{
    "items": "175",
    "sentiment_score_definition": "x <= -0.35: Bearish; -0.35 < x <= -0.15: Somewhat-Bearish; -0.15 < x < 0.15: Neutral; 0.15 <= x < 0.35: Somewhat_Bullish; x >= 0.35: Bullish",
    "relevance_score_definition": "0 < x <= 1, with a higher score indicating higher relevance.",
    "feed": [
        {
            "title": "Novo Nordisk  ( NVO )  Advances While Market Declines: Some Information for Investors",
            "url": "https://www.zacks.com/stock/news/2205299/novo-nordisk-nvo-advances-while-market-declines-some-information-for-investors",
            "time_published": "20240103T225018",
            "authors": [
                "Zacks Equity Research"
            ],
            "summary": "In the closing of the recent trading day, Novo Nordisk (NVO) stood at $103.62, denoting a +1.48% change from the preceding trading day.",
            "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default286.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.875462"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.365926"
                }
            ],
            "overall_sentiment_score": 0.208327,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "NVO",
                    "relevance_score": "0.620664",
                    "ticker_sentiment_score": "0.281241",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Use of SGLT2 Inhibitors Continues to Expand for the Treatment of Chronic Kidney Disease, with Eli Lilly/Boehringer Ingelheim's Jardiance Making Significant Strides Following Label Expansion",
            "url": "https://www.benzinga.com/pressreleases/24/01/g36478808/use-of-sglt2-inhibitors-continues-to-expand-for-the-treatment-of-chronic-kidney-disease-with-eli-l",
            "time_published": "20240103T211325",
            "authors": [
                "Globe Newswire"
            ],
            "summary": "EXTON, PA, Jan. 03, 2024 ( GLOBE NEWSWIRE ) -- Since 2019, audited records of chronic kidney disease ( CKD ) non-dialysis patients has revealed an ongoing, annual uptick in the proportion of non-diabetic CKD and diabetic kidney disease ( DKD ) patients who have received treatment with an SGLT2 ...",
            "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
            "source": "Benzinga",
            "category_within_source": "General",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.151801,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "NVO",
                    "relevance_score": "0.047749",
                    "ticker_sentiment_score": "0.020781",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Ate too much during the holidays? Now be on guard for the weight-loss scams",
            "url": "https://www.marketwatch.com/story/ate-too-much-during-the-holidays-now-be-on-guard-for-the-weight-loss-scams-e0799b8b",
            "time_published": "20240103T184200",
            "authors": [
                "Lukas I. Alpert"
            ],
            "summary": "Weight-loss drugs like Ozempic and Wegovy have been all the rage lately, but with the holiday season wrapping up, so are weight-loss scams. Experts say now is the time when ads promoting \"miracle\" weight-loss cures start popping up in droves, looking to take advantage of people who have made New ...",
            "banner_image": "https://images.mktw.net/im-815160/social",
            "source": "MarketWatch",
            "category_within_source": "Top Stories",
            "source_domain": "www.marketwatch.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": -0.152881,
            "overall_sentiment_label": "Somewhat-Bearish",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.142144",
                    "ticker_sentiment_score": "0.013073",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.142144",
                    "ticker_sentiment_score": "0.013073",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Insulin Now Available for $35 a Month for Many Americans",
            "url": "https://www.kiplinger.com/personal-finance/health-insurance/insulin-price-caps",
            "time_published": "20240103T182737",
            "authors": [
                "Joey Solitro"
            ],
            "summary": "Many Americans living with diabetes now have access to insulin for just $35 a month, thanks to price cuts that took effect on January 1. The country's three biggest insulin producers - Sanofi, Novo Nordisk and Eli Lilly - announced plans last year to cut monthly insulin prices, with some plans ...",
            "banner_image": "https://cdn.mos.cms.futurecdn.net/jEJBfhzSanqcyaGWXRcFoC-415-80.jpg",
            "source": "Kiplinger",
            "category_within_source": "n/a",
            "source_domain": "www.kiplinger.com",
            "topics": [
                {
                    "topic": "Economy - Monetary",
                    "relevance_score": "0.158519"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.158519"
                }
            ],
            "overall_sentiment_score": 0.216948,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "NVO",
                    "relevance_score": "0.162802",
                    "ticker_sentiment_score": "0.070549",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "SNY",
                    "relevance_score": "0.242084",
                    "ticker_sentiment_score": "0.081418",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Why Eli Lilly Stock Is Jumping Today While the Overall Market Is Slumping",
            "url": "https://www.fool.com/investing/2024/01/03/why-eli-lilly-stock-is-jumping-today-while-the-ove/",
            "time_published": "20240103T172011",
            "authors": [
                "Keith Speights"
            ],
            "summary": "Here's how the big pharma stock is swimming against the current.",
            "banner_image": "https://g.foolcdn.com/editorial/images/760035/ozempic.jpg",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.495866"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.161647"
                }
            ],
            "overall_sentiment_score": 0.165653,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.822443",
                    "ticker_sentiment_score": "0.223974",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.133841",
                    "ticker_sentiment_score": "0.108366",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Missed Out on Eli Lilly? My Best Pharmaceutical Stock to Buy And Hold",
            "url": "https://www.fool.com/investing/2024/01/03/missed-out-eli-lilly-best-pharmaceutical-stock/",
            "time_published": "20240103T160850",
            "authors": [
                "Justin Pope"
            ],
            "summary": "The past three years were bliss for Eli Lilly shareholders, but those not already on board should look at its rival instead.",
            "banner_image": "https://media.ycharts.com/charts/14da68206118d21fd87def9a5d059da6.png",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.682689"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.658903"
                }
            ],
            "overall_sentiment_score": 0.225488,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.592095",
                    "ticker_sentiment_score": "0.308965",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.465196",
                    "ticker_sentiment_score": "0.240351",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Here's Why You Should Bet on Rigel Pharmaceuticals  ( RIGL )  Now",
            "url": "https://www.zacks.com/stock/news/2205099/heres-why-you-should-bet-on-rigel-pharmaceuticals-rigl-now",
            "time_published": "20240103T155100",
            "authors": [
                "Zacks Equity Research"
            ],
            "summary": "Here, we discuss some reasons why buying Rigel Pharmaceuticals (RIGL) stock now may turn out to be a prudent move.",
            "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/85/906.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.928139"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.266143"
                }
            ],
            "overall_sentiment_score": 0.193209,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "RIGL",
                    "relevance_score": "0.675413",
                    "ticker_sentiment_score": "0.414776",
                    "ticker_sentiment_label": "Bullish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.211806",
                    "ticker_sentiment_score": "-0.001638",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AQST",
                    "relevance_score": "0.345674",
                    "ticker_sentiment_score": "0.044076",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "PBYI",
                    "relevance_score": "0.211806",
                    "ticker_sentiment_score": "-0.00328",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Is There A Drug To Help You Lose Fat And Gain Muscle Without Exercise?",
            "url": "https://www.forbes.com/sites/alexzhavoronkov/2024/01/03/is-there-a-drug-to-help-you-lose-fat-and-gain-muscle-without-exercise/",
            "time_published": "20240103T151740",
            "authors": [
                "Alex Zhavoronkov",
                "PhD"
            ],
            "summary": "Millions of people inject the new \"miraculous\" weight loss drugs targeting Glucagon-like peptide-1 ( GLP-1 ) such as Wegovy, Ozempic, and Mounjaro. In mere years after the launch of these drugs, their health benefits became apparent.",
            "banner_image": "https://imageio.forbes.com/specials-images/imageserve/65905b58eff9e0f2cd4ff0b8/0x0.jpg?format=jpg&crop=5152,2554,x0,y413,safe&height=900&width=1600&fit=bounds",
            "source": "Forbes",
            "category_within_source": "n/a",
            "source_domain": "www.forbes.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.145756,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "NVO",
                    "relevance_score": "0.04045",
                    "ticker_sentiment_score": "0.098434",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "UBX",
                    "relevance_score": "0.020232",
                    "ticker_sentiment_score": "0.139856",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Here's Why You Should Invest in Aquestive  ( AQST )  Stock Now",
            "url": "https://www.zacks.com/stock/news/2204853/heres-why-you-should-invest-in-aquestive-aqst-stock-now",
            "time_published": "20240103T131000",
            "authors": [
                "Zacks Equity Research"
            ],
            "summary": "Here, we discuss some reasons why buying Aquestive Therapeutics (AQST) stock now may turn out to be a prudent move.",
            "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/52/873.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.928139"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.214378"
                }
            ],
            "overall_sentiment_score": 0.072023,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "RIGL",
                    "relevance_score": "0.218325",
                    "ticker_sentiment_score": "0.099002",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.164656",
                    "ticker_sentiment_score": "-0.00136",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AQST",
                    "relevance_score": "0.420608",
                    "ticker_sentiment_score": "0.058315",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "PBYI",
                    "relevance_score": "0.164656",
                    "ticker_sentiment_score": "-0.002724",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "'Buckle up': Eli Lilly is set to 'dominate' the GLP-1 weight loss market in 2024 as Zepbound prescriptions soar, BMO says",
            "url": "https://markets.businessinsider.com/news/stocks/eli-lilly-stock-glp-1-weight-loss-zepbound-dominate-market-2024-1",
            "time_published": "20240102T181800",
            "authors": [
                "Matthew Fox"
            ],
            "summary": "Eli Lilly Stock Will 'Dominate' GLP-1 Weight Loss Market in 2024 With Zepbound - Markets Insider ...",
            "banner_image": null,
            "source": "Business Insider",
            "category_within_source": "GoogleRSS",
            "source_domain": "markets.businessinsider.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.107159,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "NVO",
                    "relevance_score": "0.172713",
                    "ticker_sentiment_score": "0.135079",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "New Year Resolution Stocks: Can Getting Fitter Be A Winner On The Stock Market? - Anheuser-Busch InBev  ( NYSE:BUD ) , Eli Lilly  ( NYSE:LLY ) ",
            "url": "https://www.benzinga.com/general/entertainment/24/01/36456513/new-year-resolution-stocks-can-getting-fitter-be-a-winner-on-the-stock-market",
            "time_published": "20240102T175811",
            "authors": [
                "Neil Dennis"
            ],
            "summary": "As another holiday season fades into memory, and we return to our desks - perhaps a little flabbier and a little hungover - will investors think about carrying over their New Year resolutions into their stock portfolios?",
            "banner_image": "https://cdn.benzinga.com/files/images/story/2024/Strong-Woman-Exercising-With-Battle-Rope.jpeg?width=1200&height=800&fit=crop",
            "source": "Benzinga",
            "category_within_source": "General",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.214378"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.5"
                }
            ],
            "overall_sentiment_score": 0.143826,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "BUD",
                    "relevance_score": "0.146469",
                    "ticker_sentiment_score": "0.063366",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "LLY",
                    "relevance_score": "0.146469",
                    "ticker_sentiment_score": "0.022267",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.146469",
                    "ticker_sentiment_score": "0.022267",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "PLNT",
                    "relevance_score": "0.420316",
                    "ticker_sentiment_score": "0.072538",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Eli Lilly  ( LLY )  Stock Up 57% in 2023: Will the Uptrend Continue?",
            "url": "https://www.zacks.com/stock/news/2204399/eli-lilly-lly-stock-up-57-in-2023-will-the-uptrend-continue",
            "time_published": "20240102T134300",
            "authors": [
                "Zacks Equity Research"
            ],
            "summary": "Lilly (LLY) is making rapid pipeline progress in areas like obesity, diabetes and Alzheimer's. Mounjaro and Zepbound are expected to be key top-line drivers for Lilly.",
            "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/fc/588.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.316726"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.838487"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.5"
                }
            ],
            "overall_sentiment_score": 0.243868,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.598368",
                    "ticker_sentiment_score": "0.380988",
                    "ticker_sentiment_label": "Bullish"
                },
                {
                    "ticker": "RIGL",
                    "relevance_score": "0.203643",
                    "ticker_sentiment_score": "0.133485",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.15347",
                    "ticker_sentiment_score": "0.044317",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AQST",
                    "relevance_score": "0.203643",
                    "ticker_sentiment_score": "0.070763",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "DICE",
                    "relevance_score": "0.051441",
                    "ticker_sentiment_score": "0.033004",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Dutch Government Blocks Exports Of ASML's Chip-Making Machines To China",
            "url": "https://www.forbes.com/sites/siladityaray/2024/01/02/dutch-government-blocks-exports-of-asmls-chip-making-machines-to-china/",
            "time_published": "20240102T082247",
            "authors": [
                "Siladitya Ray"
            ],
            "summary": "The Netherlands government revoked the export license for the shipment of some chip-making equipment made by ASML to China, the company announced Monday, once again dragging Europe's most valuable tech company and maker world's most advanced chip-making machines into an ongoing trade battle ...",
            "banner_image": "https://imageio.forbes.com/specials-images/imageserve/6593c7b147913a94a74aba94/0x0.jpg?format=jpg&crop=4557,2561,x0,y24,safe&height=900&width=1600&fit=bounds",
            "source": "Forbes",
            "category_within_source": "n/a",
            "source_domain": "www.forbes.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.5"
                }
            ],
            "overall_sentiment_score": 0.056765,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "SSNLF",
                    "relevance_score": "0.100729",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVDA",
                    "relevance_score": "0.199859",
                    "ticker_sentiment_score": "0.06699",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.100729",
                    "ticker_sentiment_score": "0.210767",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Prediction: These 3 Stocks Will Soar in 2024",
            "url": "https://www.fool.com/investing/2024/01/01/prediction-these-3-stocks-will-soar-in-2024/",
            "time_published": "20240101T115000",
            "authors": [
                "Keith Speights",
                "David Jagielski",
                "and Prosper Junior Bakiny"
            ],
            "summary": "Investors could enjoy an especially happy new year with these great stocks.",
            "banner_image": "https://g.foolcdn.com/editorial/images/759462/cheering-person-with-laptop.jpg",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.266143"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.650727"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.5"
                }
            ],
            "overall_sentiment_score": 0.196612,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "VRTX",
                    "relevance_score": "0.121241",
                    "ticker_sentiment_score": "0.009226",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "GS",
                    "relevance_score": "0.040553",
                    "ticker_sentiment_score": "0.035663",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.278109",
                    "ticker_sentiment_score": "0.148716",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AXSM",
                    "relevance_score": "0.200688",
                    "ticker_sentiment_score": "0.14049",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Is Nuveen ESG International Developed Markets Equity ETF  ( NUDM )  a Strong ETF Right Now?",
            "url": "https://www.zacks.com/stock/news/2204035/is-nuveen-esg-international-developed-markets-equity-etf-nudm-a-strong-etf-right-now",
            "time_published": "20240101T112005",
            "authors": [
                "Zacks Equity Research"
            ],
            "summary": "Smart Beta ETF report for ...",
            "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default245.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.333333"
                }
            ],
            "overall_sentiment_score": 0.186417,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "JPM",
                    "relevance_score": "0.115232",
                    "ticker_sentiment_score": "0.058659",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NSRGF",
                    "relevance_score": "0.057767",
                    "ticker_sentiment_score": "0.082964",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.057767",
                    "ticker_sentiment_score": "0.082964",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "ASML",
                    "relevance_score": "0.057767",
                    "ticker_sentiment_score": "0.082964",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "More Americans can now get insulin for $35 | Politics",
            "url": "https://www.cnn.com/2024/01/01/politics/insulin-price-cap/index.html",
            "time_published": "20240101T110000",
            "authors": [
                "Tami Luhby"
            ],
            "summary": "More Americans can now get insulin for ...",
            "banner_image": "https://media.cnn.com/api/v1/images/stellar/prod/ap22217013293155.jpg?c=16x9&q=w_800,c_fill",
            "source": "CNN",
            "category_within_source": "Markets",
            "source_domain": "www.cnn.com",
            "topics": [
                {
                    "topic": "Economy - Monetary",
                    "relevance_score": "0.451494"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.019225,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "NVO",
                    "relevance_score": "0.154455",
                    "ticker_sentiment_score": "-0.027633",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "SNY",
                    "relevance_score": "0.192387",
                    "ticker_sentiment_score": "-0.057556",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Eli Lilly Stock Jumped 59% in 2023. Is It a Good Stock to Buy in 2024?",
            "url": "https://www.fool.com/investing/2023/12/31/eli-lilly-stock-jumped-59-in-2023-is-it-a-good-sto/",
            "time_published": "20231231T103600",
            "authors": [
                "Cory Renauer"
            ],
            "summary": "Sales of its new weight-management drug could be off the charts next year.",
            "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F759654%2Finvestment-advisor-getty.jpg&op=resize&w=700",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.538269"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.962106"
                }
            ],
            "overall_sentiment_score": 0.279304,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.533678",
                    "ticker_sentiment_score": "0.416847",
                    "ticker_sentiment_label": "Bullish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.052801",
                    "ticker_sentiment_score": "0.173663",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "A 38-year-old man says 2 doses of Mounjaro permanently paralyzed his stomach. He's suing Eli Lilly.",
            "url": "https://www.businessinsider.com/mounjaro-lawsuit-alleges-stomach-is-paralyzed-from-glp-1-use-2023-12",
            "time_published": "20231230T111300",
            "authors": [
                "Hilary Brueck"
            ],
            "summary": "Lawsuit: Man alleges Mounjaro caused stomach paralysis, gastroparesis - Business Insider ...",
            "banner_image": null,
            "source": "Business Insider",
            "category_within_source": "GoogleRSS",
            "source_domain": "www.businessinsider.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": -0.093008,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "NVO",
                    "relevance_score": "0.088309",
                    "ticker_sentiment_score": "-0.072184",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Weight-loss drugs will remain out of reach for millions in 2024 as employers and insurance companies reduce coverage",
            "url": "https://www.businessinsider.com/weight-loss-drug-insurance-coverage-access-employer-2023-12",
            "time_published": "20231230T104700",
            "authors": [
                "Shelby Livingston"
            ],
            "summary": "Weight-loss drug insurance coverage, access likely to reduce in 2024 - Business Insider ...",
            "banner_image": null,
            "source": "Business Insider",
            "category_within_source": "GoogleRSS",
            "source_domain": "www.businessinsider.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Retail & Wholesale",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.333333"
                }
            ],
            "overall_sentiment_score": 0.026319,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "MS",
                    "relevance_score": "0.025379",
                    "ticker_sentiment_score": "0.078933",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.076035",
                    "ticker_sentiment_score": "-0.015636",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "WMT",
                    "relevance_score": "0.025379",
                    "ticker_sentiment_score": "0.148712",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "FT writers' predictions for the world in 2024",
            "url": "https://www.ft.com/content/7eef99e6-6bd5-4e84-85c1-ec77cc0671af",
            "time_published": "20231230T050018",
            "authors": [],
            "summary": "Forecasts for the new year, from who will win the US election to whether Musk's X is heading for bankruptcy and the future of the Parthenon marbles ...",
            "banner_image": "https://www.ft.com/__origami/service/image/v2/images/raw/https%3A%2F%2Fd1e00ek4ebabms.cloudfront.net%2Fproduction%2F731719aa-4c3d-40a8-a3b1-dfe2b16a262d.png?source=next-article&fit=scale-down&quality=highest&width=700&dpr=1",
            "source": "Financial Times",
            "category_within_source": "Markets",
            "source_domain": "www.ft.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.25"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.25"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.25"
                },
                {
                    "topic": "Economy - Monetary",
                    "relevance_score": "0.9545"
                },
                {
                    "topic": "IPO",
                    "relevance_score": "0.158519"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.929393"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.25"
                }
            ],
            "overall_sentiment_score": 0.061305,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "MSFT",
                    "relevance_score": "0.015967",
                    "ticker_sentiment_score": "0.04711",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "BCS",
                    "relevance_score": "0.015967",
                    "ticker_sentiment_score": "-0.162502",
                    "ticker_sentiment_label": "Somewhat-Bearish"
                },
                {
                    "ticker": "TSLA",
                    "relevance_score": "0.015967",
                    "ticker_sentiment_score": "-0.012385",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.015967",
                    "ticker_sentiment_score": "0.248657",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "FOREX:UYU",
                    "relevance_score": "0.015967",
                    "ticker_sentiment_score": "-0.061836",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "FOREX:JPY",
                    "relevance_score": "0.015967",
                    "ticker_sentiment_score": "0.129365",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Weight loss drugs' messy rise: How Ozempic, Wegovy, and Mounjaro really affect patients - and what comes next",
            "url": "https://www.businessinsider.com/weight-loss-glp-1-drugs-ozempic-wegovy-mounjaro-effects-future-2023-12",
            "time_published": "20231229T150000",
            "authors": [
                "Rachel Hosie",
                "Gabby Landsverk",
                "Hilary Brueck",
                "Kate Hull",
                "Shelby Livingston",
                "Mia de Graaf"
            ],
            "summary": "Weight Loss Drugs' Rise: Ozempic, Wegovy, Mounjaro Effects. Future - Business Insider ...",
            "banner_image": null,
            "source": "Business Insider",
            "category_within_source": "GoogleRSS",
            "source_domain": "www.businessinsider.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.5"
                }
            ],
            "overall_sentiment_score": 0.007302,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "GOOG",
                    "relevance_score": "0.009742",
                    "ticker_sentiment_score": "0.071359",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.068112",
                    "ticker_sentiment_score": "0.021197",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Gene Editing, Obesity Drugs And Long-Living Dogs: The Year In Biotech",
            "url": "https://www.forbes.com/sites/alexknapp/2023/12/29/gene-editing-obesity-drugs-and-long-living-dogs-the-year-in-biotech/",
            "time_published": "20231229T113000",
            "authors": [
                "Alex Knapp"
            ],
            "summary": "ike a lot of sectors, the biopharma industry kicked off a tumultuous year with a number of shakeups. Big and small biotech companies alike saw thousands of layoffs, not to mention significant leadership changes. In the startup landscape, one big change has been a strategic shift among investors.",
            "banner_image": "https://imageio.forbes.com/specials-images/imageserve/658320c5ef3e4dd3ec4375c2/0x0.jpg?format=jpg&height=900&width=1600&fit=bounds",
            "source": "Forbes",
            "category_within_source": "n/a",
            "source_domain": "www.forbes.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.161647"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.95493"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.5"
                }
            ],
            "overall_sentiment_score": 0.249292,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "VRTX",
                    "relevance_score": "0.029184",
                    "ticker_sentiment_score": "0.06454",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "GS",
                    "relevance_score": "0.029184",
                    "ticker_sentiment_score": "0.104223",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "COIN",
                    "relevance_score": "0.029184",
                    "ticker_sentiment_score": "0.072285",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.05833",
                    "ticker_sentiment_score": "0.094036",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Who was the best CEO of 2023?",
            "url": "https://www.economist.com/business/2023/12/28/who-was-the-best-ceo-of-2023",
            "time_published": "20231228T172552",
            "authors": [
                "The Economist"
            ],
            "summary": "I a tricky year atop the corporate ladder. Sluggish growth in many markets has set bosses scrambling to rein in costs just as inflation has spurred their workers to demand hefty pay rises. Fractious geopolitics and toxic culture wars have left corporate chieftains feeling like tightrope-walkers.",
            "banner_image": "https://www.economist.com/cdn-cgi/image/width=1424,quality=80,format=auto/content-assets/images/20231230_WBC815.png",
            "source": "The Economist",
            "category_within_source": "BusinessGoogleRSS",
            "source_domain": "www.economist.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Energy & Transportation",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Economy - Monetary",
                    "relevance_score": "0.158519"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.158519"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Real Estate & Construction",
                    "relevance_score": "0.2"
                }
            ],
            "overall_sentiment_score": 0.063094,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "NVDA",
                    "relevance_score": "0.120632",
                    "ticker_sentiment_score": "0.080859",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "MLSPF",
                    "relevance_score": "0.040348",
                    "ticker_sentiment_score": "0.03764",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "CCJ",
                    "relevance_score": "0.040348",
                    "ticker_sentiment_score": "0.03764",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "PHM",
                    "relevance_score": "0.040348",
                    "ticker_sentiment_score": "0.03764",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.040348",
                    "ticker_sentiment_score": "0.015711",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NU",
                    "relevance_score": "0.120632",
                    "ticker_sentiment_score": "0.055481",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "New weight loss drugs are out of reach for millions of older Americans because Medicare won't pay",
            "url": "https://apnews.com/article/wegovy-ozempic-zepbound-medicare-obesity-weight-loss-02d4500e737d30d070d70907521a4fe0",
            "time_published": "20231228T154800",
            "authors": [
                "AMANDA SEITZ"
            ],
            "summary": "WASHINGTON ( AP ) - New are showing promising results in helping some people shed pounds but the injections will remain out of reach for millions of older Americans because Medicare is forbidden to cover such medications.",
            "banner_image": "https://dims.apnews.com/dims4/default/d9ceb11/2147483647/strip/true/crop/3783x2520+0+1/resize/599x399!/quality/90/?url=https%3A%2F%2Fassets.apnews.com%2F93%2F93%2F0f6df9711285f90467d662d26a92%2F563d0bdaeeba48d6a737e3f08ccfd02e",
            "source": "Associated Press",
            "category_within_source": "Markets",
            "source_domain": "apnews.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Economy - Fiscal",
                    "relevance_score": "0.158519"
                }
            ],
            "overall_sentiment_score": 0.028848,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "NVO",
                    "relevance_score": "0.028188",
                    "ticker_sentiment_score": "-0.041678",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "The Zacks Analyst Blog Highlights Novo Nordisk, Walmart, Advanced Micro Devices, Caterpillar and Union Pacific",
            "url": "https://www.zacks.com/stock/news/2203134/the-zacks-analyst-blog-highlights-novo-nordisk-walmart-advanced-micro-devices-caterpillar-and-union-pacific",
            "time_published": "20231228T142700",
            "authors": [
                "Zacks Equity Research"
            ],
            "summary": "Novo Nordisk, Walmart, Advanced Micro Devices, Caterpillar and Union Pacific are part of the Zacks top Analyst Blog.",
            "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/91/454.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Retail & Wholesale",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.360215"
                },
                {
                    "topic": "Energy & Transportation",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.2"
                }
            ],
            "overall_sentiment_score": 0.302077,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "AMD",
                    "relevance_score": "0.378094",
                    "ticker_sentiment_score": "0.243809",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.318897",
                    "ticker_sentiment_score": "0.166905",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "UNP",
                    "relevance_score": "0.130571",
                    "ticker_sentiment_score": "0.036299",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "CAT",
                    "relevance_score": "0.130571",
                    "ticker_sentiment_score": "0.036299",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "WMT",
                    "relevance_score": "0.194763",
                    "ticker_sentiment_score": "0.046832",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Interested in the Weight-Loss Market? Here's 1 Stock to Buy Hand Over Fist in 2024, and 1 to Avoid Like the Plague.",
            "url": "https://www.fool.com/investing/2023/12/28/interested-in-the-weight-loss-market-heres-1-stock/",
            "time_published": "20231228T133000",
            "authors": [
                "Adam Spatacco"
            ],
            "summary": "While Novo Nordisk dominates the weight-loss market, there are two other stocks to consider as well.",
            "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F759102%2Fa-doctor-writing-a-prescription.jpg&op=resize&w=700",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.839681"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.503496"
                }
            ],
            "overall_sentiment_score": 0.249927,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.532043",
                    "ticker_sentiment_score": "0.439982",
                    "ticker_sentiment_label": "Bullish"
                },
                {
                    "ticker": "SGEN",
                    "relevance_score": "0.096283",
                    "ticker_sentiment_score": "-0.030773",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.19117",
                    "ticker_sentiment_score": "0.124512",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "PFE",
                    "relevance_score": "0.454714",
                    "ticker_sentiment_score": "0.146467",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Biden administration's Medicare drug price negotiations will face major tests in 2024",
            "url": "https://www.cnbc.com/2023/12/28/medicare-drug-price-negotiations-whats-ahead-in-2024.html",
            "time_published": "20231228T120001",
            "authors": [
                "Annika Kim Constantino"
            ],
            "summary": "Next year could set the precedent for the Inflation Reduction Act's controversial talks, which could affect dozens of medications by the end of the decade.",
            "banner_image": "https://image.cnbcfm.com/api/v1/image/107130655-1665090556176-gettyimages-1431082899-_m021740_4b5641b7-17d1-48f7-8db3-6aef2e513b99.jpeg?v=1702616299&w=1920&h=1080",
            "source": "CNBC",
            "category_within_source": "Business",
            "source_domain": "www.cnbc.com",
            "topics": [
                {
                    "topic": "Economy - Monetary",
                    "relevance_score": "0.310843"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.538269"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.5"
                }
            ],
            "overall_sentiment_score": 0.021634,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "GOOG",
                    "relevance_score": "0.029399",
                    "ticker_sentiment_score": "0.166075",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "ABBV",
                    "relevance_score": "0.029399",
                    "ticker_sentiment_score": "0.173879",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "AZN",
                    "relevance_score": "0.088039",
                    "ticker_sentiment_score": "0.008287",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.058759",
                    "ticker_sentiment_score": "-0.059983",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "BMY",
                    "relevance_score": "0.1172",
                    "ticker_sentiment_score": "-0.026135",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.1172",
                    "ticker_sentiment_score": "-0.026135",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Could Pfizer Be a No-Brainer Stock to Buy Right Now, Even If Its COVID Sales Continue to Plunge?",
            "url": "https://www.fool.com/investing/2023/12/28/could-pfizer-be-a-no-brainer-stock-to-buy-right-no/",
            "time_published": "20231228T105000",
            "authors": [
                "Keith Speights"
            ],
            "summary": "COVID-19 products Comirnaty and Paxlovid are no longer Pfizer's crown jewels. But that's OK.",
            "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F759358%2Fchart-3.png&op=resize&w=700",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.796627"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.503496"
                }
            ],
            "overall_sentiment_score": 0.142183,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "NVO",
                    "relevance_score": "0.051441",
                    "ticker_sentiment_score": "0.110018",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "PFE",
                    "relevance_score": "0.754476",
                    "ticker_sentiment_score": "0.202336",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Top Analyst Reports for Novo Nordisk, Walmart & AMD",
            "url": "https://www.zacks.com/research-daily/2202579/top-analyst-reports-for-novo-nordisk-walmart-amd",
            "time_published": "20231227T213900",
            "authors": [
                "Mark Vickery"
            ],
            "summary": "Today's Research Daily features new research reports on 16 major stocks, including Novo Nordisk A/S (NVO), Walmart Inc. (WMT) and Advanced Micro Devices, Inc. (AMD).",
            "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/e0/51032.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.360215"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.36426,
            "overall_sentiment_label": "Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "NVO",
                    "relevance_score": "0.179121",
                    "ticker_sentiment_score": "0.186038",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Why You Should Invest in Encompass Health  ( EHC )  Stock for Now",
            "url": "https://www.zacks.com/stock/news/2202750/why-you-should-invest-in-encompass-health-ehc-stock-for-now",
            "time_published": "20231227T164400",
            "authors": [
                "Zacks Equity Research"
            ],
            "summary": "Encompass Health (EHC) is well-poised for growth on the back of growing revenues, an aging U.S. population, joint ventures and solid cash reserves.",
            "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/8e/1155.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.161647"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.995869"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.5"
                }
            ],
            "overall_sentiment_score": 0.285777,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "PEN",
                    "relevance_score": "0.107016",
                    "ticker_sentiment_score": "0.055162",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "CNC",
                    "relevance_score": "0.159922",
                    "ticker_sentiment_score": "0.067921",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "EHC",
                    "relevance_score": "0.653656",
                    "ticker_sentiment_score": "0.492339",
                    "ticker_sentiment_label": "Bullish"
                },
                {
                    "ticker": "HCSG",
                    "relevance_score": "0.053629",
                    "ticker_sentiment_score": "0.221833",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.107016",
                    "ticker_sentiment_score": "0.055162",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Spotlight on Novo Nordisk: Analyzing the Surge in Options Activity - Novo Nordisk  ( NYSE:NVO ) ",
            "url": "https://www.benzinga.com/markets/options/23/12/36400075/spotlight-on-novo-nordisk-analyzing-the-surge-in-options-activity",
            "time_published": "20231227T163108",
            "authors": [
                "Benzinga Insights"
            ],
            "summary": "Whales with a lot of money to spend have taken a noticeably bearish stance on Novo Nordisk. Looking at options history for Novo Nordisk NVO we detected 10 trades. If we consider the specifics of each trade, it is accurate to state that 20% of the investors opened trades with bullish expectations ...",
            "banner_image": "https://cdn.benzinga.com/files/images/story/2023/movers_image_5.jpeg?width=1200&height=800&fit=crop",
            "source": "Benzinga",
            "category_within_source": "Markets",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.360215"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.365926"
                }
            ],
            "overall_sentiment_score": 0.129629,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "NVO",
                    "relevance_score": "0.602879",
                    "ticker_sentiment_score": "0.263416",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "A Tale of Two Pharmas: Can Obesity Firms Continue Their Outperformance in 2024?",
            "url": "https://www.wsj.com/health/pharma/a-tale-of-two-pharmas-can-obesity-firms-continue-their-outperformance-in-2024-96242f04",
            "time_published": "20231227T143900",
            "authors": [
                "David Wainer"
            ],
            "summary": "In pharma, a company can take a larger slice of the healthcare pie than peers, but it is still constrained by the size of the pie.",
            "banner_image": "https://images.wsj.net/im-905482/social",
            "source": "Wall Street Journal",
            "category_within_source": "Markets",
            "source_domain": "www.wsj.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": -0.059788,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "NVO",
                    "relevance_score": "0.303175",
                    "ticker_sentiment_score": "-0.092107",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Three Stocks to Watch: $350 or $150 First?, Biotech's Buying Bonanza, and the $1 Billion \"I'm Sorry\" - Money Morning",
            "url": "https://moneymorning.com/2023/12/27/three-stocks-to-watch-350-or-150-first-biotechs-buying-bonanza-and-the-1-billion-im-sorry/",
            "time_published": "20231227T125621",
            "authors": [],
            "summary": "Three Stocks to Watch: $350 or $150 First?, Biotech's Buying Bonanza, and the $1 Billion \"I'm Sorry\" Money Morning ...",
            "banner_image": null,
            "source": "Money Morning",
            "category_within_source": "GoogleRSS",
            "source_domain": "moneymorning.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.25"
                },
                {
                    "topic": "Energy & Transportation",
                    "relevance_score": "0.25"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.25"
                },
                {
                    "topic": "Economy - Monetary",
                    "relevance_score": "0.158519"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.108179"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.25"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.360215"
                }
            ],
            "overall_sentiment_score": 0.002402,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "TSLA",
                    "relevance_score": "0.272788",
                    "ticker_sentiment_score": "0.245578",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NIO",
                    "relevance_score": "0.183895",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.183895",
                    "ticker_sentiment_score": "0.235046",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "RYZB",
                    "relevance_score": "0.272788",
                    "ticker_sentiment_score": "0.078528",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "ABBV",
                    "relevance_score": "0.092569",
                    "ticker_sentiment_score": "0.109511",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "FDX",
                    "relevance_score": "0.183895",
                    "ticker_sentiment_score": "-0.214868",
                    "ticker_sentiment_label": "Somewhat-Bearish"
                },
                {
                    "ticker": "BMY",
                    "relevance_score": "0.183895",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Is FlexShares International Quality Dividend ETF  ( IQDF )  a Strong ETF Right Now?",
            "url": "https://www.zacks.com/stock/news/2202435/is-flexshares-international-quality-dividend-etf-iqdf-a-strong-etf-right-now",
            "time_published": "20231227T112005",
            "authors": [
                "Zacks Equity Research"
            ],
            "summary": "Smart Beta ETF report for ...",
            "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default336.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Energy & Transportation",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.333333"
                }
            ],
            "overall_sentiment_score": 0.255493,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "BHP",
                    "relevance_score": "0.111488",
                    "ticker_sentiment_score": "0.044939",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NTRS",
                    "relevance_score": "0.274012",
                    "ticker_sentiment_score": "0.234718",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "RBCPF",
                    "relevance_score": "0.055881",
                    "ticker_sentiment_score": "0.040909",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.055881",
                    "ticker_sentiment_score": "0.040909",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "AstraZeneca to buy cancer drug developer for up to $1.2 billion",
            "url": "https://www.financialexpress.com/healthcare/pharma-healthcare/astrazeneca-to-buy-cancer-drug-developer-for-up-to-1-2-billion/3347920/",
            "time_published": "20231227T033000",
            "authors": [
                "Bloomberg"
            ],
            "summary": "AstraZeneca Plc agreed to acquire Chinese cell therapy developer Gracell Biotechnologies Inc. for as much as $1.2 billion as the British drug giant bolsters its bets on medical innovation in the world's second-biggest economy.",
            "banner_image": "https://www.financialexpress.com/wp-content/uploads/2023/12/cancer-gc50db6a0c_1920-1.jpg",
            "source": "The Financial Express",
            "category_within_source": "n/a",
            "source_domain": "www.financialexpress.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.289381,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "PTAIF",
                    "relevance_score": "0.263942",
                    "ticker_sentiment_score": "0.286876",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "AZN",
                    "relevance_score": "0.133841",
                    "ticker_sentiment_score": "0.165942",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "GRCL",
                    "relevance_score": "0.133841",
                    "ticker_sentiment_score": "0.165942",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.133841",
                    "ticker_sentiment_score": "0.10071",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Sarepta  ( SRPT )  Seeks Label Expansion for DMD Gene Therapy",
            "url": "https://www.zacks.com/stock/news/2202279/sarepta-srpt-seeks-label-expansion-for-dmd-gene-therapy",
            "time_published": "20231226T163500",
            "authors": [
                "Zacks Equity Research"
            ],
            "summary": "Sarepta (SRPT) files a supplement with the FDA seeking to expand its recently-approved gene therapy Elevidys' label to treat all DMD patients, regardless of age and ambulatory status.",
            "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/7b/850.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.838487"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.21003,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "GLPG",
                    "relevance_score": "0.479258",
                    "ticker_sentiment_score": "0.10529",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "SRPT",
                    "relevance_score": "0.21686",
                    "ticker_sentiment_score": "0.15791",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.28636",
                    "ticker_sentiment_score": "0.166465",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": " ( NVO )  - Analyzing Novo Nordisk's Short Interest - Novo Nordisk  ( NYSE:NVO ) ",
            "url": "https://www.benzinga.com/short-sellers/23/12/36379843/nvo-analyzing-novo-nordisks-short-interest",
            "time_published": "20231225T184511",
            "authors": [
                "Benzinga Insights"
            ],
            "summary": "Novo Nordisk's NVO short percent of float has fallen 5.71% since its last report. The company recently reported that it has 5.60 million shares sold short, which is 0.33% of all regular shares that are available for trading.",
            "banner_image": "https://cdn.benzinga.com/files/images/story/2023/movers_image_5.jpeg?width=1200&height=800&fit=crop",
            "source": "Benzinga",
            "category_within_source": "Trading",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.365926"
                }
            ],
            "overall_sentiment_score": 0.239316,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "NVO",
                    "relevance_score": "0.221819",
                    "ticker_sentiment_score": "0.083071",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Structure Therapeutics Stock Just Crashed. Here's Why It Could Be Worth Buying Now",
            "url": "https://www.fool.com/investing/2023/12/25/structure-therapeutics-stock-just-crashed-heres/",
            "time_published": "20231225T124500",
            "authors": [
                "Alex Carchidi"
            ],
            "summary": "It has genuine struggles ahead, but it has some actual value in hand as well.",
            "banner_image": "https://g.foolcdn.com/editorial/images/758922/stressed-investor-at-laptop.jpg",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.990999"
                }
            ],
            "overall_sentiment_score": 0.127143,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.12023",
                    "ticker_sentiment_score": "0.176753",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "GPCR",
                    "relevance_score": "0.12023",
                    "ticker_sentiment_score": "0.062485",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.040212",
                    "ticker_sentiment_score": "0.011782",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "The Nine Breakthroughs of the Year",
            "url": "https://www.theatlantic.com/ideas/archive/2023/12/scientific-breakthroughs-2023-list/676952/",
            "time_published": "20231225T110000",
            "authors": [
                "Derek Thompson"
            ],
            "summary": "This is Work in Progress, a newsletter about work, technology, and how to solve some of America's biggest problems. Sign up here. The theme of my second-annual Breakthroughs of the Year is the long road of progress. My top breakthrough is Casgevy, a gene-editing treatment for sickle-cell anemia.",
            "banner_image": "https://cdn.theatlantic.com/thumbor/_nv7L0KkiZ0RIF6apGC39d1BCIw=/0x43:2000x1085/1200x625/media/img/mt/2023/12/breakthroughs/original.gif",
            "source": "The Atlantic",
            "category_within_source": "n/a",
            "source_domain": "www.theatlantic.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.25"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.25"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.25"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.25"
                }
            ],
            "overall_sentiment_score": 0.120445,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "NYT",
                    "relevance_score": "0.013379",
                    "ticker_sentiment_score": "0.126719",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "VRTX",
                    "relevance_score": "0.013379",
                    "ticker_sentiment_score": "-0.030885",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "GOOG",
                    "relevance_score": "0.013379",
                    "ticker_sentiment_score": "0.093169",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "MS",
                    "relevance_score": "0.013379",
                    "ticker_sentiment_score": "0.071524",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.026755",
                    "ticker_sentiment_score": "0.068026",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "PFE",
                    "relevance_score": "0.013379",
                    "ticker_sentiment_score": "0.087075",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Novo Nordisk, Maker Of 'Miracle' Weight Loss Drug Ozempic, Announces Mega Factory In Dublin - Novo Nordisk  ( NYSE:NVO ) ",
            "url": "https://www.benzinga.com/general/biotech/23/12/36377030/novo-nordisk-maker-of-miracle-weight-loss-drug-ozempic-announces-mega-factory-in-dublin",
            "time_published": "20231224T163239",
            "authors": [
                "Anan Ashraf"
            ],
            "summary": "Novo Nordisk A/S NVO, the maker of 'Miracle' weight loss drugs Ozempic and Wegovy, is reportedly set to construct a large-scale manufacturing facility in Dublin as demand surges for its weight-loss drugs.",
            "banner_image": "https://cdn.benzinga.com/files/images/story/2023/OZempic-Insulin.jpeg?width=1200&height=800&fit=crop",
            "source": "Benzinga",
            "category_within_source": "News",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.108179"
                }
            ],
            "overall_sentiment_score": 0.158774,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "ALKS",
                    "relevance_score": "0.172097",
                    "ticker_sentiment_score": "0.152535",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.33628",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Could Ginkgo Bioworks Stock Help You Become a Millionaire?",
            "url": "https://www.fool.com/investing/2023/12/24/could-ginkgo-bioworks-stock-help-you-become-a-mill/",
            "time_published": "20231224T131000",
            "authors": [
                "David Jagielski"
            ],
            "summary": "It's easy to see a way for this to be a huge business in the future, but the path ahead of it is by no means a smooth one.",
            "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F758862%2Fginkgo-bioworks-active-programs.png&op=resize&w=700",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.99793"
                }
            ],
            "overall_sentiment_score": 0.291738,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "DNA",
                    "relevance_score": "0.315628",
                    "ticker_sentiment_score": "0.334277",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.064797",
                    "ticker_sentiment_score": "0.086356",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "PFE",
                    "relevance_score": "0.064797",
                    "ticker_sentiment_score": "0.086356",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "BIIB",
                    "relevance_score": "0.064797",
                    "ticker_sentiment_score": "0.086356",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Will Novo Nordisk Be Worth More Than Meta Platforms by 2030?",
            "url": "https://www.fool.com/investing/2023/12/23/will-novo-nordisk-worth-more-meta-platform-2030/",
            "time_published": "20231223T121000",
            "authors": [
                "David Jagielski"
            ],
            "summary": "The gap in market cap between these two companies is big today, but it could shrink in the future.",
            "banner_image": "https://g.foolcdn.com/editorial/images/758863/a-group-of-scientists-looking-at-a-report.jpg",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.962106"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.360215"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.5"
                }
            ],
            "overall_sentiment_score": 0.264607,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "GOOG",
                    "relevance_score": "0.051663",
                    "ticker_sentiment_score": "0.109487",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "META",
                    "relevance_score": "0.523995",
                    "ticker_sentiment_score": "0.329448",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.482982",
                    "ticker_sentiment_score": "0.508228",
                    "ticker_sentiment_label": "Bullish"
                },
                {
                    "ticker": "FOREX:DKK",
                    "relevance_score": "0.051663",
                    "ticker_sentiment_score": "0.067846",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "FOREX:NOK",
                    "relevance_score": "0.051663",
                    "ticker_sentiment_score": "0.067846",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Ozempic, Wegovy and other weight loss drugs present holiday challenges",
            "url": "https://www.foxbusiness.com/lifestyle/ozempic-wegovy-weight-loss-drugs-holidays",
            "time_published": "20231222T205200",
            "authors": [
                "Aislinn Murphy"
            ],
            "summary": "Celebrating the winter holidays for many means buying presents, arranging travel and planning hefty menus for meals with loved ones. However, this year those preparations may include skipping medications popularly used to facilitate weight loss.",
            "banner_image": "https://cf-images.us-east-1.prod.boltdns.net/v1/static/854081161001/95229286-9a4b-4424-82fe-b7446fbb76bb/62736bc3-4f8e-4219-b9af-c20478b40e56/1280x720/match/image.jpg",
            "source": "Fox Business News",
            "category_within_source": "n/a",
            "source_domain": "www.foxbusiness.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.00244,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "NVO",
                    "relevance_score": "0.07031",
                    "ticker_sentiment_score": "0.120608",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Novo Nordisk, FDA warn of fake Ozempic",
            "url": "https://www.marketwatch.com/story/novo-nordisk-fda-warn-of-fake-ozempic-6dca2448",
            "time_published": "20231222T180100",
            "authors": [
                "Eleanor Laise"
            ],
            "summary": "The FDA has seized thousands of units of fake Ozempic, the agency said Thursday.",
            "banner_image": "https://images.mktw.net/im-31318914/social",
            "source": "MarketWatch",
            "category_within_source": "Top Stories",
            "source_domain": "www.marketwatch.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": -0.080132,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "NVO",
                    "relevance_score": "0.570165",
                    "ticker_sentiment_score": "-0.114884",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Jazz Pharmaceuticals'  ( JAZZ )  PTSD Drug Misses Study Goals",
            "url": "https://www.zacks.com/stock/news/2201716/jazz-pharmaceuticals-jazz-ptsd-drug-misses-study-goals",
            "time_published": "20231222T170700",
            "authors": [
                "Zacks Equity Research"
            ],
            "summary": "After a mid-stage study fails to show any improvement in its primary or secondary endpoints, Jazz (JAZZ) plans to scrap the development of its PTSD drug.",
            "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/21/594.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.838487"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.5"
                }
            ],
            "overall_sentiment_score": 0.014552,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "BNOX",
                    "relevance_score": "0.275091",
                    "ticker_sentiment_score": "0.281546",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "GLPG",
                    "relevance_score": "0.461997",
                    "ticker_sentiment_score": "0.105907",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "JAZZ",
                    "relevance_score": "0.275091",
                    "ticker_sentiment_score": "-0.213868",
                    "ticker_sentiment_label": "Somewhat-Bearish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.275091",
                    "ticker_sentiment_score": "0.163182",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Biotech stocks set for a rebound in 2024, analysts say",
            "url": "https://www.marketwatch.com/story/biotech-stocks-set-for-a-rebound-in-2024-analysts-say-24df6236",
            "time_published": "20231222T160600",
            "authors": [
                "Eleanor Laise"
            ],
            "summary": "A more favorable interest-rate outlook, an uptick in deals, and innovations in key areas like cancer and immunology are setting up biotech for a brighter 2024, analysts say.",
            "banner_image": "https://images.mktw.net/im-15783720/social",
            "source": "MarketWatch",
            "category_within_source": "Top Stories",
            "source_domain": "www.marketwatch.com",
            "topics": [
                {
                    "topic": "Economy - Monetary",
                    "relevance_score": "0.310843"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "IPO",
                    "relevance_score": "0.158519"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.495866"
                }
            ],
            "overall_sentiment_score": 0.133016,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "NVO",
                    "relevance_score": "0.089129",
                    "ticker_sentiment_score": "0.156557",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "MRUS",
                    "relevance_score": "0.089129",
                    "ticker_sentiment_score": "0.080617",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "KRTX",
                    "relevance_score": "0.089129",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "VRTX",
                    "relevance_score": "0.089129",
                    "ticker_sentiment_score": "-0.1576",
                    "ticker_sentiment_label": "Somewhat-Bearish"
                },
                {
                    "ticker": "IRON",
                    "relevance_score": "0.089129",
                    "ticker_sentiment_score": "0.033685",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AMGN",
                    "relevance_score": "0.17715",
                    "ticker_sentiment_score": "0.070894",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "PFE",
                    "relevance_score": "0.089129",
                    "ticker_sentiment_score": "-0.009465",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "BMY",
                    "relevance_score": "0.089129",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "VKTX",
                    "relevance_score": "0.089129",
                    "ticker_sentiment_score": "0.203569",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "AZN",
                    "relevance_score": "0.089129",
                    "ticker_sentiment_score": "0.085373",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "BMRN",
                    "relevance_score": "0.089129",
                    "ticker_sentiment_score": "-0.1576",
                    "ticker_sentiment_label": "Somewhat-Bearish"
                },
                {
                    "ticker": "LLY",
                    "relevance_score": "0.089129",
                    "ticker_sentiment_score": "0.111772",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "BPMC",
                    "relevance_score": "0.089129",
                    "ticker_sentiment_score": "-0.1576",
                    "ticker_sentiment_label": "Somewhat-Bearish"
                },
                {
                    "ticker": "SGEN",
                    "relevance_score": "0.044634",
                    "ticker_sentiment_score": "-0.008934",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "FDA says fake Ozempic shots are being sold through some legitimate sources",
            "url": "https://apnews.com/article/ozempic-fake-counterfeit-semaglutide-86d152c78f180792e7764a435cb3334d",
            "time_published": "20231222T153400",
            "authors": [
                "JONEL ALECCIA"
            ],
            "summary": "The U.S. Food and Drug Administration said it has seized \"thousands of units\" of , the diabetes drug widely used for weight loss, that had been distributed through legitimate drug supply sources. The FDA and the drug's maker, Novo Nordisk, are testing the shots.",
            "banner_image": "https://dims.apnews.com/dims4/default/5e964d1/2147483647/strip/true/crop/687x457+157+0/resize/320x213!/quality/90/?url=https%3A%2F%2Fassets.apnews.com%2F4e%2F15%2F46525d610d8c36292d9b21bbc591%2Fd6ce78193a6442608b362b9f26440684",
            "source": "Associated Press",
            "category_within_source": "Markets",
            "source_domain": "apnews.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.5"
                }
            ],
            "overall_sentiment_score": 0.059571,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "HHH",
                    "relevance_score": "0.192694",
                    "ticker_sentiment_score": "0.250384",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.192694",
                    "ticker_sentiment_score": "-0.001583",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Pharma Stock Roundup: FDA Nod to AZN's Eplontersen, CRL to MRK's Cough Candidate",
            "url": "https://www.zacks.com/stock/news/2201507/pharma-stock-roundup-fda-nod-to-azns-eplontersen-crl-to-mrks-cough-candidate",
            "time_published": "20231222T142100",
            "authors": [
                "Kinjel Shah"
            ],
            "summary": "FDA approves AstraZeneca (AZN) and Ionis' (IONS) Wainua (eplontersen) for ATTRv-PN and gives CRL to Merck's chronic cough candidate, gefapixant.",
            "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/5d/2633.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.214378"
                }
            ],
            "overall_sentiment_score": 0.058124,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "AZN",
                    "relevance_score": "0.253866",
                    "ticker_sentiment_score": "0.14725",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.04303",
                    "ticker_sentiment_score": "-0.117624",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "ABBV",
                    "relevance_score": "0.04303",
                    "ticker_sentiment_score": "-0.122577",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "SGEN",
                    "relevance_score": "0.085936",
                    "ticker_sentiment_score": "-0.08266",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "ICVX",
                    "relevance_score": "0.04303",
                    "ticker_sentiment_score": "-0.211222",
                    "ticker_sentiment_label": "Somewhat-Bearish"
                },
                {
                    "ticker": "PFE",
                    "relevance_score": "0.170878",
                    "ticker_sentiment_score": "-0.179093",
                    "ticker_sentiment_label": "Somewhat-Bearish"
                },
                {
                    "ticker": "SNY",
                    "relevance_score": "0.170878",
                    "ticker_sentiment_score": "-0.109563",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Here are the big health sector themes to watch next year",
            "url": "https://www.cnbc.com/2023/12/22/health-sector-themes-to-watch-in-2024.html",
            "time_published": "20231222T134109",
            "authors": [
                "Bertha Coombs"
            ],
            "summary": "The health-care sector has seen a big rebound this month, and analysts say some beaten-down names will continue to have positive momentum in 2024.",
            "banner_image": "https://image.cnbcfm.com/api/v1/image/106886059-16215272662021-05-20t161326z_1086106208_rc2sjn9cwi51_rtrmadp_0_pharmaceuticals-easteurope.jpeg?v=1621527339&w=1920&h=1080",
            "source": "CNBC",
            "category_within_source": "Business",
            "source_domain": "www.cnbc.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Economy - Monetary",
                    "relevance_score": "0.310843"
                },
                {
                    "topic": "IPO",
                    "relevance_score": "0.310843"
                },
                {
                    "topic": "Retail & Wholesale",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.77141"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.614606"
                },
                {
                    "topic": "Mergers & Acquisitions",
                    "relevance_score": "0.310843"
                }
            ],
            "overall_sentiment_score": 0.144638,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "CVS",
                    "relevance_score": "0.050679",
                    "ticker_sentiment_score": "0.116952",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "HUM",
                    "relevance_score": "0.101154",
                    "ticker_sentiment_score": "0.215236",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "BAC",
                    "relevance_score": "0.025352",
                    "ticker_sentiment_score": "0.362517",
                    "ticker_sentiment_label": "Bullish"
                },
                {
                    "ticker": "JPM",
                    "relevance_score": "0.025352",
                    "ticker_sentiment_score": "0.033066",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.025352",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "GS",
                    "relevance_score": "0.025352",
                    "ticker_sentiment_score": "0.054743",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AVTR",
                    "relevance_score": "0.025352",
                    "ticker_sentiment_score": "0.1296",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "PFE",
                    "relevance_score": "0.025352",
                    "ticker_sentiment_score": "-0.087163",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "UNH",
                    "relevance_score": "0.025352",
                    "ticker_sentiment_score": "0.110094",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "ABT",
                    "relevance_score": "0.025352",
                    "ticker_sentiment_score": "0.075078",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "PODD",
                    "relevance_score": "0.050679",
                    "ticker_sentiment_score": "0.083415",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "QGEN",
                    "relevance_score": "0.025352",
                    "ticker_sentiment_score": "0.1296",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "MRNA",
                    "relevance_score": "0.025352",
                    "ticker_sentiment_score": "-0.087163",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "DXCM",
                    "relevance_score": "0.050679",
                    "ticker_sentiment_score": "0.083415",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Fake Ozempic - FDA and Novo Nordisk Warn Against Counterfeit Ozempic Penetrating US Market Amid High Demand - Novo Nordisk  ( NYSE:NVO ) ",
            "url": "https://www.benzinga.com/general/biotech/23/12/36358915/fake-ozempic-fda-and-novo-nordisk-warn-against-counterfeit-ozempic-penetrating-us-market-amid-hig",
            "time_published": "20231222T125229",
            "authors": [
                "Vandana Singh"
            ],
            "summary": "The FDA on Thursday said it continues to investigate counterfeit Novo Nordisk A/S's NVO Ozempic ( semaglutide ) injection of 1 milligram ( mg ) in the legitimate U.S. drug supply chain and has seized thousands of units of the diabetes drug.",
            "banner_image": "https://cdn.benzinga.com/files/images/story/2023/12/22/ozempic.png?width=1200&height=800&fit=crop",
            "source": "Benzinga",
            "category_within_source": "General",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.014512,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "NVO",
                    "relevance_score": "0.522333",
                    "ticker_sentiment_score": "0.189828",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Novo Nordisk A/S - share repurchase programme",
            "url": "https://www.globenewswire.com/news-release/2023/12/22/2800529/0/en/Novo-Nordisk-A-S-share-repurchase-programme.html",
            "time_published": "20231222T115200",
            "authors": [
                "Novo Nordisk A/S"
            ],
            "summary": "Bagsvrd, Denmark, 22 December 2023 - On 6 November 2023, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 ( MAR ) and the Commission Delegated Regulation ( EU ) 2016/1052 of 8 March ...",
            "banner_image": "https://ml-eu.globenewswire.com/Resource/Download/18c2fb08-e2c1-4a52-90dd-5c0f18213eb6",
            "source": "GlobeNewswire",
            "category_within_source": "n/a",
            "source_domain": "www.globenewswire.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.360215"
                }
            ],
            "overall_sentiment_score": 0.122936,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "GOOG",
                    "relevance_score": "0.122269",
                    "ticker_sentiment_score": "0.045242",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "META",
                    "relevance_score": "0.122269",
                    "ticker_sentiment_score": "0.045242",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.781591",
                    "ticker_sentiment_score": "0.195779",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Transcript: The year of weight loss drugs",
            "url": "https://www.ft.com/content/698c4a63-ee42-4847-a9ac-798c5567cdc0",
            "time_published": "20231222T050043",
            "authors": [],
            "summary": "This is an audio transcript of the FT News Briefing podcast episode: 'The year of weight loss drugs' Good morning from the Financial Times. Today is Friday, December 22nd. And this is your FT News Briefing. The Bank of England could start cutting rates next year.",
            "banner_image": "https://www.ft.com/__origami/service/image/v2/images/raw/https%3A%2F%2Fd1e00ek4ebabms.cloudfront.net%2Fproduction%2F3e8bd0f3-f321-4fbe-93c6-64b53b632ad6.jpg?source=next-article&fit=scale-down&quality=highest&width=700&dpr=1",
            "source": "Financial Times",
            "category_within_source": "GoogleRSS",
            "source_domain": "www.ft.com",
            "topics": [
                {
                    "topic": "Economy - Monetary",
                    "relevance_score": "0.158519"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.108179"
                },
                {
                    "topic": "Mergers & Acquisitions",
                    "relevance_score": "0.158519"
                }
            ],
            "overall_sentiment_score": 0.078808,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "NVO",
                    "relevance_score": "0.04161",
                    "ticker_sentiment_score": "0.08861",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "The year of weight-loss drugs",
            "url": "https://www.ft.com/content/6ebece34-20f6-4e06-bdc2-b086f2135e7f",
            "time_published": "20231222T050016",
            "authors": [],
            "summary": "Chancellor Jeremy Hunt raised the prospect of the Bank of England reducing interest rates in 2024 in an interview with the FT, and Novo Nordisk's drugs for obesity could have a profound effect on healthcare, society and our relationship with food.",
            "banner_image": "https://www.ft.com/__origami/service/image/v2/images/raw/https%3A%2F%2Fwww.ft.com%2F__origami%2Fservice%2Fimage%2Fv2%2Fimages%2Fraw%2Fhttps%253A%252F%252Fnext-video-editor-images.s3.ap-northeast-1.amazonaws.com%252F40c429e6-c63a-4ced-ac62-3b877334a69a%3Fsource%3Dnext-article%26fit%3Dscale-down%26quality%3Dhighest%26width%3D700%26dpr%3D1?source=next-opengraph&fit=scale-down&width=900",
            "source": "Financial Times",
            "category_within_source": "GoogleRSS",
            "source_domain": "www.ft.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.198632,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "NVO",
                    "relevance_score": "0.233556",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "FDA says it's seized 'thousands of units' of counterfeit Ozempic",
            "url": "https://www.cnn.com/2023/12/21/health/fda-counterfeit-ozempic/index.html",
            "time_published": "20231222T015431",
            "authors": [
                "Jen Christensen"
            ],
            "summary": "FDA says it's seized 'thousands of units' of counterfeit ...",
            "banner_image": "https://media.cnn.com/api/v1/images/stellar/prod/231221180414-counterfeit-ozempic-label-fda.jpg?c=16x9&q=w_800,c_fill",
            "source": "CNN",
            "category_within_source": "Markets",
            "source_domain": "www.cnn.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": -0.13388,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "WBD",
                    "relevance_score": "0.109455",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.417995",
                    "ticker_sentiment_score": "-0.386535",
                    "ticker_sentiment_label": "Bearish"
                }
            ]
        },
        {
            "title": "Stocks Bounce With Inflation Data Due; Six Stocks To Watch",
            "url": "https://www.investors.com/market-trend/stock-market-today/dow-jones-futures-market-rebounds-with-key-inflation-data-due-apple-leads-stocks-to-watch/",
            "time_published": "20231221T214800",
            "authors": [
                "ED CARSON",
                "Investor's Business Daily"
            ],
            "summary": "Dow Jones Futures: Market Rebounds With Key Inflation Data Due. Apple Leads Stocks To Watch Investor's Business Daily ...",
            "banner_image": "https://www.investors.com/wp-content/uploads/2019/08/stock-bounce-back-01-adobe.jpg",
            "source": "Investors Business Daily",
            "category_within_source": "n/a",
            "source_domain": "www.investors.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.25"
                },
                {
                    "topic": "Energy & Transportation",
                    "relevance_score": "0.25"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.25"
                },
                {
                    "topic": "Economy - Monetary",
                    "relevance_score": "0.576289"
                },
                {
                    "topic": "Economy - Fiscal",
                    "relevance_score": "0.310843"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.25"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.818451"
                }
            ],
            "overall_sentiment_score": 0.13611,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "MSFT",
                    "relevance_score": "0.205308",
                    "ticker_sentiment_score": "0.084713",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "GOOG",
                    "relevance_score": "0.059268",
                    "ticker_sentiment_score": "-0.019059",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AAPL",
                    "relevance_score": "0.262052",
                    "ticker_sentiment_score": "0.006002",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.176502",
                    "ticker_sentiment_score": "0.010328",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "SMCI",
                    "relevance_score": "0.088799",
                    "ticker_sentiment_score": "0.069807",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "LLY",
                    "relevance_score": "0.059268",
                    "ticker_sentiment_score": "0.012047",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "MASI",
                    "relevance_score": "0.059268",
                    "ticker_sentiment_score": "0.044035",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NKE",
                    "relevance_score": "0.176502",
                    "ticker_sentiment_score": "0.072379",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "CCL",
                    "relevance_score": "0.088799",
                    "ticker_sentiment_score": "0.004201",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Rybelsus vs. Ozempic For Weight Loss: What's The Difference?",
            "url": "https://www.forbes.com/health/weight-loss/rybelsus-vs-ozempic/",
            "time_published": "20231221T213142",
            "authors": [
                "Heidi Borst"
            ],
            "summary": "Both Rybelsus and Ozempic are manufactured by the drug company Novo Nordisk, says Dr. Comite. Their main differences are the route of administration, frequency and strength.",
            "banner_image": "https://thumbor.forbes.com/thumbor/fit-in/x/https://www.forbes.com/health/wp-content/uploads/2023/12/Rybelsus-vs.-Ozempic-For-Weight-Loss-Whats-The-Difference-e1703058314700.jpg",
            "source": "Forbes",
            "category_within_source": "n/a",
            "source_domain": "www.forbes.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": -0.154165,
            "overall_sentiment_label": "Somewhat-Bearish",
            "ticker_sentiment": [
                {
                    "ticker": "NVO",
                    "relevance_score": "0.18967",
                    "ticker_sentiment_score": "-0.099473",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Monthly Meeting Q&A with Jim Cramer: Stock buying and selling strategies into year end",
            "url": "https://www.cnbc.com/2023/12/21/monthly-meeting-qa-with-jim-cramer-stock-buying-and-selling-strategies-into-year-end.html",
            "time_published": "20231221T180706",
            "authors": [
                "Paulina Likos"
            ],
            "summary": "During the December Monthly Meeting, we took questions directly from Investing Club members.",
            "banner_image": "https://image.cnbcfm.com/api/v1/image/107204415-1678206782470-Eaton_Corporation-OB-Photo-MW-20230307-0001-PRESS-1.JPG?v=1678381479&w=600&h=300&vtcrop=y",
            "source": "CNBC",
            "category_within_source": "Top News",
            "source_domain": "www.cnbc.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.166667"
                },
                {
                    "topic": "Energy & Transportation",
                    "relevance_score": "0.166667"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.166667"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.166667"
                },
                {
                    "topic": "Economy - Monetary",
                    "relevance_score": "0.158519"
                },
                {
                    "topic": "Retail & Wholesale",
                    "relevance_score": "0.166667"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.166667"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.769861"
                }
            ],
            "overall_sentiment_score": 0.10348,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "HUM",
                    "relevance_score": "0.136666",
                    "ticker_sentiment_score": "0.054069",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVDA",
                    "relevance_score": "0.058807",
                    "ticker_sentiment_score": "0.043109",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "VMW",
                    "relevance_score": "0.058807",
                    "ticker_sentiment_score": "0.043109",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AVGO",
                    "relevance_score": "0.058807",
                    "ticker_sentiment_score": "0.043109",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "JPM",
                    "relevance_score": "0.019618",
                    "ticker_sentiment_score": "0.039266",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.019618",
                    "ticker_sentiment_score": "0.039266",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.019618",
                    "ticker_sentiment_score": "0.039266",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NYT",
                    "relevance_score": "0.019618",
                    "ticker_sentiment_score": "0.039266",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "SLB",
                    "relevance_score": "0.019618",
                    "ticker_sentiment_score": "0.039266",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "COST",
                    "relevance_score": "0.078354",
                    "ticker_sentiment_score": "0.044336",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "WFC",
                    "relevance_score": "0.039224",
                    "ticker_sentiment_score": "0.042455",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "CAT",
                    "relevance_score": "0.058807",
                    "ticker_sentiment_score": "0.043109",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "LLY",
                    "relevance_score": "0.117295",
                    "ticker_sentiment_score": "0.050055",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "PEP",
                    "relevance_score": "0.019618",
                    "ticker_sentiment_score": "0.039266",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "FDX",
                    "relevance_score": "0.019618",
                    "ticker_sentiment_score": "0.039266",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "HD",
                    "relevance_score": "0.019618",
                    "ticker_sentiment_score": "0.039266",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AMZN",
                    "relevance_score": "0.155954",
                    "ticker_sentiment_score": "0.058574",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "CTRA",
                    "relevance_score": "0.058807",
                    "ticker_sentiment_score": "0.043109",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Universal Health  ( UHS )  Up 17% in 3 Months: More Growth Ahead?",
            "url": "https://www.zacks.com/stock/news/2201204/universal-health-uhs-up-17-in-3-months-more-growth-ahead",
            "time_published": "20231221T173300",
            "authors": [
                "Zacks Equity Research"
            ],
            "summary": "Universal Health (UHS) is well-poised for growth on the back of the resumption of elective procedures, acquisitions and solid operating cash flows.",
            "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/7b/2387.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.986413"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.108179"
                }
            ],
            "overall_sentiment_score": 0.290333,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "UHS",
                    "relevance_score": "0.151858",
                    "ticker_sentiment_score": "0.199929",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "PODD",
                    "relevance_score": "0.201523",
                    "ticker_sentiment_score": "0.163044",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "DXCM",
                    "relevance_score": "0.250386",
                    "ticker_sentiment_score": "0.193123",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "HCSG",
                    "relevance_score": "0.101582",
                    "ticker_sentiment_score": "0.166345",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.201523",
                    "ticker_sentiment_score": "0.163044",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Merck's  ( MRK )  Chronic Cough Drug Gets Another CRL From FDA",
            "url": "https://www.zacks.com/stock/news/2201156/mercks-mrk-chronic-cough-drug-gets-another-crl-from-fda",
            "time_published": "20231221T163800",
            "authors": [
                "Zacks Equity Research"
            ],
            "summary": "Per the FDA, the data submitted by Merck (MRK) for its chronic cough drug did not provide sufficient evidence to prove its clinical benefit in patients.",
            "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/20/2483.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.838487"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.071869,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "GLPG",
                    "relevance_score": "0.421485",
                    "ticker_sentiment_score": "0.099657",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "GSK",
                    "relevance_score": "0.308504",
                    "ticker_sentiment_score": "-0.055996",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.249106",
                    "ticker_sentiment_score": "0.150674",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Here's How Much $1000 Invested In Novo Nordisk 10 Years Ago Would Be Worth Today - Novo Nordisk  ( NYSE:NVO ) ",
            "url": "https://www.benzinga.com/news/23/12/36344841/heres-how-much-1000-invested-in-novo-nordisk-10-years-ago-would-be-worth-today",
            "time_published": "20231221T150025",
            "authors": [
                "Benzinga Insights"
            ],
            "summary": "Novo Nordisk NVO has outperformed the market over the past 10 years by 9.16% on an annualized basis producing an average annual return of 19.04%. Currently, Novo Nordisk has a market capitalization of $458.45 billion.",
            "banner_image": "https://cdn.benzinga.com/files/images/story/2023/valuestock_image_4.jpeg?width=1200&height=800&fit=crop",
            "source": "Benzinga",
            "category_within_source": "Trading",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.108179"
                }
            ],
            "overall_sentiment_score": 0.160819,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "NVO",
                    "relevance_score": "0.980595",
                    "ticker_sentiment_score": "0.386944",
                    "ticker_sentiment_label": "Bullish"
                }
            ]
        },
        {
            "title": "Weighing Their Chances: 5 Leading Healthcare Companies Fight for Market Share in the $100 Billion Weight-Loss Industry",
            "url": "https://www.fool.com/investing/2023/12/21/weighing-their-chances-5-leading-healthcare-compan/",
            "time_published": "20231221T144500",
            "authors": [
                "David Jagielski"
            ],
            "summary": "Which weight-loss stocks are good buys today?",
            "banner_image": "https://g.foolcdn.com/editorial/images/758496/a-doctor-looking-at-a-tablet-with-another-person.jpg",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.360215"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.158519"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.5"
                }
            ],
            "overall_sentiment_score": 0.18264,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.290607",
                    "ticker_sentiment_score": "0.215295",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "GS",
                    "relevance_score": "0.049526",
                    "ticker_sentiment_score": "0.131126",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AZN",
                    "relevance_score": "0.33628",
                    "ticker_sentiment_score": "0.091332",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.290607",
                    "ticker_sentiment_score": "0.215295",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "PFE",
                    "relevance_score": "0.243864",
                    "ticker_sentiment_score": "0.100877",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Pacira Appoints Frank D. Lee as Chief Executive Officer",
            "url": "https://www.globenewswire.com/news-release/2023/12/21/2799921/0/en/Pacira-Appoints-Frank-D-Lee-as-Chief-Executive-Officer.html",
            "time_published": "20231221T123000",
            "authors": [
                "Pacira Pharmaceuticals",
                "Inc."
            ],
            "summary": "-- Transformational Leader Brings Three Decades of Global Experience in Pharmaceutical and Biotechnology Product Development and Commercialization -- -- Paul J. Hastings Named Chair of the Board ...",
            "banner_image": "https://ml.globenewswire.com/Resource/Download/4bcac699-a2cd-44c4-8009-e141be88e8ad",
            "source": "GlobeNewswire",
            "category_within_source": "n/a",
            "source_domain": "www.globenewswire.com",
            "topics": [
                {
                    "topic": "Economy - Monetary",
                    "relevance_score": "0.158519"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.988915"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.360215"
                }
            ],
            "overall_sentiment_score": 0.113608,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "HLCO",
                    "relevance_score": "0.013843",
                    "ticker_sentiment_score": "-0.055295",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "BOLT",
                    "relevance_score": "0.027683",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "PCRX",
                    "relevance_score": "0.082915",
                    "ticker_sentiment_score": "0.144757",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.013843",
                    "ticker_sentiment_score": "0.071097",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "3 Nationwide Mutual Funds to Add to Your Portfolio",
            "url": "https://www.zacks.com/stock/news/2200875/3-nationwide-mutual-funds-to-add-to-your-portfolio",
            "time_published": "20231221T112800",
            "authors": [
                "Zacks Equity Research"
            ],
            "summary": "Invest in Nationwide mutual funds such as NWAMX, NWXEX and NWHLX for great returns.",
            "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/ad/591.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.977154"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.333333"
                }
            ],
            "overall_sentiment_score": 0.286205,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "AMDUF",
                    "relevance_score": "0.072217",
                    "ticker_sentiment_score": "0.178455",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "CYPXF",
                    "relevance_score": "0.072217",
                    "ticker_sentiment_score": "0.175419",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NMR",
                    "relevance_score": "0.072217",
                    "ticker_sentiment_score": "0.093591",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "CSCO",
                    "relevance_score": "0.072217",
                    "ticker_sentiment_score": "0.050272",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "JPM",
                    "relevance_score": "0.072217",
                    "ticker_sentiment_score": "0.050272",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.072217",
                    "ticker_sentiment_score": "0.043228",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "BRK-A",
                    "relevance_score": "0.072217",
                    "ticker_sentiment_score": "0.050272",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "ASML",
                    "relevance_score": "0.072217",
                    "ticker_sentiment_score": "0.043228",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "InnovationRx: Obamacare Enrollment Is Hitting New Highs",
            "url": "https://www.forbes.com/sites/alexknapp/2023/12/20/innovationrx-obamacare-enrollment-is-hitting-new-highs/",
            "time_published": "20231220T222954",
            "authors": [
                "Alex Knapp"
            ],
            "summary": "InnovationRx is your weekly digest of healthcare news. To get it in your inbox, subscribe here.",
            "banner_image": "https://imageio.forbes.com/specials-images/imageserve/658369a79a7fab73ccc117ef/0x0.jpg?format=jpg&height=900&width=1600&fit=bounds",
            "source": "Forbes",
            "category_within_source": "n/a",
            "source_domain": "www.forbes.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.083653,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "GKOS",
                    "relevance_score": "0.056674",
                    "ticker_sentiment_score": "0.02002",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "RADCQ",
                    "relevance_score": "0.168884",
                    "ticker_sentiment_score": "-0.146898",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "ARQT",
                    "relevance_score": "0.056674",
                    "ticker_sentiment_score": "0.096926",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.056674",
                    "ticker_sentiment_score": "0.02739",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "PFE",
                    "relevance_score": "0.056674",
                    "ticker_sentiment_score": "-0.096824",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Why Novo Nordisk Stock Was Up on a Down Day for the Market",
            "url": "https://www.fool.com/investing/2023/12/20/why-novo-nordisk-stock-was-up-on-a-down-day-for-th/",
            "time_published": "20231220T215800",
            "authors": [
                "Eric Volkman"
            ],
            "summary": "As if the company's top two products weren't popular enough, a new media report made them even more appealing.",
            "banner_image": "https://g.foolcdn.com/editorial/images/758999/patient-and-physician-smiling-during-a-visit.jpg",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.5"
                }
            ],
            "overall_sentiment_score": 0.085754,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "NYT",
                    "relevance_score": "0.121037",
                    "ticker_sentiment_score": "0.202516",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.239305",
                    "ticker_sentiment_score": "0.249476",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Two-thirds of people on weight-loss drugs plan to eat healthy during the holidays",
            "url": "https://www.marketwatch.com/story/a-smaller-christmas-feast-66-of-people-on-weight-loss-drugs-plan-to-eat-healthy-during-the-holidays-e0133bc7",
            "time_published": "20231220T170200",
            "authors": [
                "Charles Passy"
            ],
            "summary": "A new survey points to how people on GLP-1 medications, such as Ozempic and Saxenda, are changing their approach to holiday dining.",
            "banner_image": "https://images.mktw.net/im-93673476/social",
            "source": "MarketWatch",
            "category_within_source": "Top Stories",
            "source_domain": "www.marketwatch.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.5"
                }
            ],
            "overall_sentiment_score": 0.10703,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "RMCF",
                    "relevance_score": "0.229149",
                    "ticker_sentiment_score": "0.069805",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.115787",
                    "ticker_sentiment_score": "0.044745",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "FDA Accepts Merck's  ( MRK )  BLA for 21-Valent Pneumococcal Jab",
            "url": "https://www.zacks.com/stock/news/2200645/fda-accepts-mercks-mrk-bla-for-21-valent-pneumococcal-jab",
            "time_published": "20231220T163900",
            "authors": [
                "Zacks Equity Research"
            ],
            "summary": "The FDA grants priority review to Merck's (MRK) filing seeking approval for its 21-valent pneumococcal conjugate vaccine in adults. A final decision is expected in June 2024.",
            "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/ef/472.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.838487"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.157391,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "GLPG",
                    "relevance_score": "0.415535",
                    "ticker_sentiment_score": "0.098691",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.245339",
                    "ticker_sentiment_score": "0.14884",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "PFE",
                    "relevance_score": "0.303926",
                    "ticker_sentiment_score": "0.170888",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Five obesity-drug trends to watch in 2024: Who can compete with Eli Lilly and Novo Nordisk?",
            "url": "https://www.marketwatch.com/story/five-obesity-drug-trends-to-watch-in-2024-who-can-compete-with-eli-lilly-and-novo-nordisk-1dc62a7d",
            "time_published": "20231220T161700",
            "authors": [
                "Eleanor Laise"
            ],
            "summary": "The obesity drugs that powered huge investor gains in 2023 are poised to inspire more corporate dealmaking, scientific breakthroughs and better patient access in the year ahead, analysts say.",
            "banner_image": "https://images.mktw.net/im-80508866/social",
            "source": "MarketWatch",
            "category_within_source": "Top Stories",
            "source_domain": "www.marketwatch.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.161647"
                }
            ],
            "overall_sentiment_score": 0.119145,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "VKTX",
                    "relevance_score": "0.043778",
                    "ticker_sentiment_score": "0.087169",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AZN",
                    "relevance_score": "0.043778",
                    "ticker_sentiment_score": "-0.046832",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.087424",
                    "ticker_sentiment_score": "0.081911",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "LLY",
                    "relevance_score": "0.237288",
                    "ticker_sentiment_score": "0.153064",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "ALT",
                    "relevance_score": "0.043778",
                    "ticker_sentiment_score": "0.083222",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "GPCR",
                    "relevance_score": "0.043778",
                    "ticker_sentiment_score": "-0.018675",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "MORN",
                    "relevance_score": "0.021897",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AMGN",
                    "relevance_score": "0.043778",
                    "ticker_sentiment_score": "0.200504",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "PFE",
                    "relevance_score": "0.065625",
                    "ticker_sentiment_score": "-0.017049",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "These 2 Unstoppable Stocks Could Make You Richer in 2024 and Beyond",
            "url": "https://www.fool.com/investing/2023/12/20/these-2-unstoppable-stocks-could-make-you-richer/",
            "time_published": "20231220T141500",
            "authors": [
                "Adam Spatacco"
            ],
            "summary": "Eli Lilly and Novo Nordisk are disrupting the weight-loss market with treatments like Mounjaro and Ozempic.",
            "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F758466%2Fdoctor-with-senior-man.jpg&op=resize&w=700",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.413559"
                }
            ],
            "overall_sentiment_score": 0.286799,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.440549",
                    "ticker_sentiment_score": "0.362886",
                    "ticker_sentiment_label": "Bullish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.552001",
                    "ticker_sentiment_score": "0.417987",
                    "ticker_sentiment_label": "Bullish"
                }
            ]
        },
        {
            "title": "4 Drug Stocks Rising More Than 40% in 2023 With Room to Grow",
            "url": "https://www.zacks.com/stock/news/2200461/4-drug-stocks-rising-more-than-40-in-2023-with-room-to-grow",
            "time_published": "20231220T134500",
            "authors": [
                "Kinjel Shah"
            ],
            "summary": "Novo Nordisk (NVO), Journey Medical Corporation (DERM), Lyra Therapeutics (LYRA) and Fusion Pharmaceuticals (FUSN) have returned 40% or higher year to date and have room for more growth in 2024.",
            "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/39/612.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.214378"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.310843"
                },
                {
                    "topic": "Mergers & Acquisitions",
                    "relevance_score": "0.451494"
                }
            ],
            "overall_sentiment_score": 0.202206,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "DERM",
                    "relevance_score": "0.196079",
                    "ticker_sentiment_score": "0.131587",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "FUSN",
                    "relevance_score": "0.163909",
                    "ticker_sentiment_score": "0.131476",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AZN",
                    "relevance_score": "0.033006",
                    "ticker_sentiment_score": "0.167425",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.22792",
                    "ticker_sentiment_score": "0.139365",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "LYRA",
                    "relevance_score": "0.098794",
                    "ticker_sentiment_score": "0.040116",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "The world this year 2023 | Dec 23rd 2023 Edition",
            "url": "https://www.economist.com/the-world-this-week/2023/12/20/the-world-this-year-2023",
            "time_published": "20231220T134215",
            "authors": [
                "The Economist"
            ],
            "summary": "Less than six months after celebrating the 75th anniversary of its founding, Israel suffered its worst-ever terrorist attack. On October 7th Hamas militants crossed from Gaza and went on a rampage in the surrounding area, killing 1,200 people, 364 of them at a music festival.",
            "banner_image": "https://www.economist.com/cdn-cgi/image/width=1424,quality=80,format=auto/content-assets/images/20231223_WWP004.jpg",
            "source": "The Economist",
            "category_within_source": "BusinessGoogleRSS",
            "source_domain": "www.economist.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.25"
                },
                {
                    "topic": "Energy & Transportation",
                    "relevance_score": "0.25"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.25"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.25"
                },
                {
                    "topic": "Economy - Monetary",
                    "relevance_score": "0.928139"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.161647"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.158519"
                }
            ],
            "overall_sentiment_score": -0.179294,
            "overall_sentiment_label": "Somewhat-Bearish",
            "ticker_sentiment": [
                {
                    "ticker": "MSFT",
                    "relevance_score": "0.022815",
                    "ticker_sentiment_score": "0.040183",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "FRC",
                    "relevance_score": "0.022815",
                    "ticker_sentiment_score": "-0.160739",
                    "ticker_sentiment_label": "Somewhat-Bearish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.022815",
                    "ticker_sentiment_score": "0.040183",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "XOM",
                    "relevance_score": "0.022815",
                    "ticker_sentiment_score": "-0.101768",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "RCL",
                    "relevance_score": "0.022815",
                    "ticker_sentiment_score": "0.040183",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "SBNY",
                    "relevance_score": "0.022815",
                    "ticker_sentiment_score": "-0.160739",
                    "ticker_sentiment_label": "Somewhat-Bearish"
                },
                {
                    "ticker": "PXD",
                    "relevance_score": "0.022815",
                    "ticker_sentiment_score": "-0.101768",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "FOREX:UYU",
                    "relevance_score": "0.022815",
                    "ticker_sentiment_score": "-0.003782",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Martin Glensbjerg takes up new position at ChemoMetec",
            "url": "https://www.globenewswire.com/news-release/2023/12/20/2799277/0/en/Martin-Glensbjerg-takes-up-new-position-at-ChemoMetec.html",
            "time_published": "20231220T133500",
            "authors": [
                "Chemometec A/S"
            ],
            "summary": "ANNOUNCEMENT NO. ...",
            "banner_image": "https://ml-eu.globenewswire.com/Resource/Download/dda6d08e-1d43-433e-bc7b-b1e84b4963be",
            "source": "GlobeNewswire",
            "category_within_source": "n/a",
            "source_domain": "www.globenewswire.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.360215"
                }
            ],
            "overall_sentiment_score": 0.237334,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "AZN",
                    "relevance_score": "0.090474",
                    "ticker_sentiment_score": "0.042426",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.090474",
                    "ticker_sentiment_score": "0.042426",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.090474",
                    "ticker_sentiment_score": "0.042426",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Weight loss drugs, Alzheimer's treatments and gene editing: Enormous firsts defined 2023 in pharma",
            "url": "https://www.cnbc.com/2023/12/20/weight-loss-drugs-covid-downturn-pharma-had-a-year-full-of-firsts.html",
            "time_published": "20231220T120001",
            "authors": [
                "Annika Kim Constantino"
            ],
            "summary": "Wall Street turned its focus to a handful of newer treatments in different disease areas in 2023, including weight loss medications and a new Alzheimer's drug.",
            "banner_image": "https://image.cnbcfm.com/api/v1/image/107347356-1702499004188-gettyimages-1839792823-roy-notitle231211_np5rX.jpeg?v=1702499083&w=1920&h=1080",
            "source": "CNBC",
            "category_within_source": "Business",
            "source_domain": "www.cnbc.com",
            "topics": [
                {
                    "topic": "Economy - Monetary",
                    "relevance_score": "0.158519"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.161647"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.938793"
                }
            ],
            "overall_sentiment_score": 0.016958,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "AZN",
                    "relevance_score": "0.053992",
                    "ticker_sentiment_score": "0.045817",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.08091",
                    "ticker_sentiment_score": "-0.013704",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.053992",
                    "ticker_sentiment_score": "-0.015961",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "ABBV",
                    "relevance_score": "0.027011",
                    "ticker_sentiment_score": "0.172126",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "MRNA",
                    "relevance_score": "0.053992",
                    "ticker_sentiment_score": "-0.091089",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "ESALF",
                    "relevance_score": "0.107736",
                    "ticker_sentiment_score": "0.068154",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "PFE",
                    "relevance_score": "0.08091",
                    "ticker_sentiment_score": "0.132047",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "BIIB",
                    "relevance_score": "0.08091",
                    "ticker_sentiment_score": "0.05643",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "BMY",
                    "relevance_score": "0.053992",
                    "ticker_sentiment_score": "-0.015961",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "From AI and inflation to Elon Musk and Taylor Swift, the business stories that dominated 2023",
            "url": "https://apnews.com/article/inflation-ai-musk-unions-homes-taylor-swift-bfead409df9b22fc9b688a48efc1010f",
            "time_published": "20231220T080000",
            "authors": [
                "KEN SWEET",
                "PAUL WISEMAN"
            ],
            "summary": "Artificial intelligence went mainstream - for good or ill. Labor unions capitalized on their growing might to win more generous pay and benefits. Elon Musk renamed and rebranded the social media platform Twitter, removed guardrails against phony or obscene posts and ranted profanely when ...",
            "banner_image": "https://dims.apnews.com/dims4/default/14a3f61/2147483647/strip/true/crop/8640x5755+0+2/resize/599x399!/quality/90/?url=https%3A%2F%2Fassets.apnews.com%2Fdf%2F75%2F9c60ffb6b43f1dd6c4efd37cd5e9%2F1aa582cac76f485aa3a750ba7a5d915c",
            "source": "Associated Press",
            "category_within_source": "Markets",
            "source_domain": "apnews.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.25"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.25"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.25"
                },
                {
                    "topic": "Blockchain",
                    "relevance_score": "0.310843"
                },
                {
                    "topic": "Economy - Monetary",
                    "relevance_score": "0.999937"
                },
                {
                    "topic": "Economy - Fiscal",
                    "relevance_score": "0.158519"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.999162"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.25"
                }
            ],
            "overall_sentiment_score": -0.024561,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "NVDA",
                    "relevance_score": "0.020921",
                    "ticker_sentiment_score": "0.130211",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "FRC",
                    "relevance_score": "0.020921",
                    "ticker_sentiment_score": "-0.201676",
                    "ticker_sentiment_label": "Somewhat-Bearish"
                },
                {
                    "ticker": "GM",
                    "relevance_score": "0.020921",
                    "ticker_sentiment_score": "0.021759",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "JPM",
                    "relevance_score": "0.020921",
                    "ticker_sentiment_score": "-0.184876",
                    "ticker_sentiment_label": "Somewhat-Bearish"
                },
                {
                    "ticker": "MS",
                    "relevance_score": "0.020921",
                    "ticker_sentiment_score": "0.084004",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.020921",
                    "ticker_sentiment_score": "0.130211",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "CCZ",
                    "relevance_score": "0.020921",
                    "ticker_sentiment_score": "0.021001",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "SBNY",
                    "relevance_score": "0.041828",
                    "ticker_sentiment_score": "-0.202848",
                    "ticker_sentiment_label": "Somewhat-Bearish"
                },
                {
                    "ticker": "COIN",
                    "relevance_score": "0.020921",
                    "ticker_sentiment_score": "-0.135171",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "FOREX:USD",
                    "relevance_score": "0.020921",
                    "ticker_sentiment_score": "0.130211",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "CRYPTO:BTC",
                    "relevance_score": "0.041828",
                    "ticker_sentiment_score": "0.132441",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Novo Nordisk Collaborates With India's Online Marketplace To Remove Unauthorized Wegovy Listings - Novo Nordisk  ( NYSE:NVO ) ",
            "url": "https://www.benzinga.com/general/biotech/23/12/36300585/novo-nordisk-collaborates-with-indias-online-marketplace-to-remove-unauthorized-wegovy-listings",
            "time_published": "20231219T155330",
            "authors": [
                "Vandana Singh"
            ],
            "summary": "IndiaMART, an online marketplace in India, has reportedly taken action to remove unauthorized listings of Novo Nordisk A/S's NVO highly sought-after weight-loss drug Wegovy after engaging in discussions with the Danish pharmaceutical company earlier this month.",
            "banner_image": "https://cdn.benzinga.com/files/images/story/2023/12/19/wegovy_.png?width=1200&height=800&fit=crop",
            "source": "Benzinga",
            "category_within_source": "General",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.012168,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "NVO",
                    "relevance_score": "0.648497",
                    "ticker_sentiment_score": "0.216773",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Pfizer  ( PFE )  Stock Rises on FDA Nod for Expanded Use of Padcev",
            "url": "https://www.zacks.com/stock/news/2200049/pfizer-pfe-stock-rises-on-fda-nod-for-expanded-use-of-padcev",
            "time_published": "20231219T152800",
            "authors": [
                "Zacks Equity Research"
            ],
            "summary": "The FDA approves Pfizer's (PFE) Padcev in combination with Merck's (MRK) Keytruda for adult patients with advanced bladder cancer. Stock rises 1.6%.",
            "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/89/447.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.890401"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.161647"
                }
            ],
            "overall_sentiment_score": 0.060675,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "NVO",
                    "relevance_score": "0.192694",
                    "ticker_sentiment_score": "0.056581",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "PFE",
                    "relevance_score": "0.374312",
                    "ticker_sentiment_score": "-0.069602",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "SGEN",
                    "relevance_score": "0.374312",
                    "ticker_sentiment_score": "-0.10486",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Merck  ( MRK )  Gets EU Nod for Expanded Use in Gastric Cancer",
            "url": "https://www.zacks.com/stock/news/2200047/merck-mrk-gets-eu-nod-for-expanded-use-in-gastric-cancer",
            "time_published": "20231219T152700",
            "authors": [
                "Zacks Equity Research"
            ],
            "summary": "Following these approvals, Merck's (MRK) Keytruda is approved for seven gastrointestinal cancers in the European Union. Overall, the drug is approved for 26 indications in the region.",
            "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/ef/472.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.9545"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.220647,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "GLPG",
                    "relevance_score": "0.373911",
                    "ticker_sentiment_score": "0.086224",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.219312",
                    "ticker_sentiment_score": "0.126156",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "OCUP",
                    "relevance_score": "0.165409",
                    "ticker_sentiment_score": "0.052446",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Alexandria  ( ARE )  Inks Leases at its Campuses Amid Solid Demand",
            "url": "https://www.zacks.com/stock/news/2200025/alexandria-are-inks-leases-at-its-campuses-amid-solid-demand",
            "time_published": "20231219T150100",
            "authors": [
                "Zacks Equity Research"
            ],
            "summary": "Amid the booming demand for life-science assets, Alexandria (ARE) inks leases with Novo Nordisk and CARGO at its mega campuses in Greater Boston and San Carlos in the San Francisco Bay Area.",
            "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/71/24435.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.161647"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.158519"
                },
                {
                    "topic": "Real Estate & Construction",
                    "relevance_score": "0.5"
                }
            ],
            "overall_sentiment_score": 0.355052,
            "overall_sentiment_label": "Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "ARE",
                    "relevance_score": "0.066414",
                    "ticker_sentiment_score": "0.048259",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.197413",
                    "ticker_sentiment_score": "0.094387",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "CRGX",
                    "relevance_score": "0.132368",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Daily: A Fight To Stop Dangerous Fakes Of Weight Loss Drug Wegovy",
            "url": "https://www.forbes.com/sites/forbesdaily/2023/12/19/forbes-daily-a-fight-to-stop-dangerous-fakes-of-weight-loss-drug-wegovy/",
            "time_published": "20231219T132346",
            "authors": [
                "Danielle Chemtob"
            ],
            "summary": "Forbes Daily: Novo Nordisk fights fakes of weight loss drug Wegovy Forbes ...",
            "banner_image": "https://imageio.forbes.com/specials-images/imageserve/658198f816b7e094f3f08386/0x0.jpg?format=jpg&crop=5197,2925,x0,y260,safe&height=900&width=1600&fit=bounds",
            "source": "Forbes",
            "category_within_source": "n/a",
            "source_domain": "www.forbes.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.25"
                },
                {
                    "topic": "Economy - Fiscal",
                    "relevance_score": "0.158519"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.858979"
                },
                {
                    "topic": "Real Estate & Construction",
                    "relevance_score": "0.25"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.25"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.25"
                }
            ],
            "overall_sentiment_score": 0.070495,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "GOOG",
                    "relevance_score": "0.060694",
                    "ticker_sentiment_score": "0.041009",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "BAC",
                    "relevance_score": "0.020249",
                    "ticker_sentiment_score": "0.15887",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NKLA",
                    "relevance_score": "0.020249",
                    "ticker_sentiment_score": "-0.134169",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.020249",
                    "ticker_sentiment_score": "-0.058604",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NISTF",
                    "relevance_score": "0.020249",
                    "ticker_sentiment_score": "0.090006",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "MASI",
                    "relevance_score": "0.020249",
                    "ticker_sentiment_score": "-0.025531",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "SCHW",
                    "relevance_score": "0.020249",
                    "ticker_sentiment_score": "0.090006",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "FOREX:UYU",
                    "relevance_score": "0.020249",
                    "ticker_sentiment_score": "0.097921",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Healthcare companies are promising to help patients quit Wegovy. There's just one problem with that.",
            "url": "https://www.businessinsider.com/quit-wegovy-ozempic-no-evidence-stop-taking-works-2023-12",
            "time_published": "20231219T105700",
            "authors": [
                "Shelby Livingston"
            ],
            "summary": "Companies say you can quit Wegovy - but there's no evidence it works - Business Insider ...",
            "banner_image": null,
            "source": "Business Insider",
            "category_within_source": "GoogleRSS",
            "source_domain": "www.businessinsider.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": -0.019418,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "NVO",
                    "relevance_score": "0.069495",
                    "ticker_sentiment_score": "0.028217",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "The Zacks Analyst Blog Highlights Novo Nordisk, Eli Lilly, Vertex Pharmaceuticals, Regeneron and GSK",
            "url": "https://www.zacks.com/stock/news/2199740/the-zacks-analyst-blog-highlights-novo-nordisk-eli-lilly-vertex-pharmaceuticals-regeneron-and-gsk",
            "time_published": "20231219T093400",
            "authors": [
                "Zacks Investment Research"
            ],
            "summary": "Novo Nordisk, Eli Lilly, Vertex Pharmaceuticals, Regeneron and GSK are included in this Analyst Blog.",
            "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/fc/588.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Economy - Monetary",
                    "relevance_score": "0.158519"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.990999"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.890401"
                },
                {
                    "topic": "Mergers & Acquisitions",
                    "relevance_score": "0.451494"
                }
            ],
            "overall_sentiment_score": 0.198286,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.200134",
                    "ticker_sentiment_score": "0.176485",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "VRTX",
                    "relevance_score": "0.067347",
                    "ticker_sentiment_score": "0.08218",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "GSK",
                    "relevance_score": "0.156316",
                    "ticker_sentiment_score": "0.133696",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.200134",
                    "ticker_sentiment_score": "0.143776",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "SNY",
                    "relevance_score": "0.022473",
                    "ticker_sentiment_score": "0.021801",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Obesity/Diabetes Drug Class GLP-1s' Cost-Saving Potential: Decoding Impact on Healthcare Spending - Novo Nordisk  ( NYSE:NVO ) , Eli Lilly  ( NYSE:LLY ) ",
            "url": "https://www.benzinga.com/analyst-ratings/analyst-color/23/12/36287829/obesitydiabetes-drug-class-glp-1s-cost-saving-potential-decoding-impact-on-healthca",
            "time_published": "20231218T193936",
            "authors": [
                "Vandana Singh"
            ],
            "summary": "Due to the recent achievements of GLP-1s, Goldman Sachs sees significant potential for Eli Lilly And Co LLY, Novo Nordisk A/S NVO, and other companies to venture into categories that exceed the scope of consideration for most investors at present.",
            "banner_image": "https://cdn.benzinga.com/files/images/story/2023/12/18/ozempic.png?width=1200&height=800&fit=crop",
            "source": "Benzinga",
            "category_within_source": "General",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.360215"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.77141"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.5"
                }
            ],
            "overall_sentiment_score": 0.154855,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "GS",
                    "relevance_score": "0.094762",
                    "ticker_sentiment_score": "0.171373",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "LLY",
                    "relevance_score": "0.188193",
                    "ticker_sentiment_score": "0.240368",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.188193",
                    "ticker_sentiment_score": "0.240368",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Eli Lilly stock could soar 140% by 2028 as more people use weight-loss drugs, Goldman says",
            "url": "https://markets.businessinsider.com/news/stocks/eli-lilly-stock-price-outlook-glp1-weight-loss-drug-growth-2023-12",
            "time_published": "20231218T183100",
            "authors": [
                "Matthew Fox"
            ],
            "summary": "Eli Lilly Stock Outlook Has 140% Upside Amid GLP-1 Drug Growth: Goldman - Markets Insider ...",
            "banner_image": null,
            "source": "Business Insider",
            "category_within_source": "GoogleRSS",
            "source_domain": "markets.businessinsider.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.214378"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.905476"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.5"
                }
            ],
            "overall_sentiment_score": 0.275721,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "GS",
                    "relevance_score": "0.164656",
                    "ticker_sentiment_score": "0.101819",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.110209",
                    "ticker_sentiment_score": "0.22797",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Wegovy's Success Spurs Novo Nordisk Foundation's Philanthropic Initiative To Enhance Respiratory Disease Vaccines - Novo Nordisk  ( NYSE:NVO ) ",
            "url": "https://www.benzinga.com/general/biotech/23/12/36282551/wegovys-success-spurs-novo-nordisk-foundations-philanthropic-initiative-to-enhance-respiratory-di",
            "time_published": "20231218T172331",
            "authors": [
                "Vandana Singh"
            ],
            "summary": "The Novo Nordisk Foundation pledged 1.8 billion Danish crowns ( $265 million ) toward an initiative to enhance vaccines for respiratory illnesses.",
            "banner_image": "https://cdn.benzinga.com/files/images/story/2023/12/18/wegovy-company.png?width=1200&height=800&fit=crop",
            "source": "Benzinga",
            "category_within_source": "General",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.022039,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "NVO",
                    "relevance_score": "0.777888",
                    "ticker_sentiment_score": "0.306354",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Why Novo Nordisk Stock Is Moving Higher Today",
            "url": "https://www.fool.com/investing/2023/12/18/why-novo-nordisk-stock-is-moving-higher-today/",
            "time_published": "20231218T155350",
            "authors": [
                "Keith Speights"
            ],
            "summary": "An Indian e-commerce company is helping Novo Nordisk combat illegal sales of weight loss drug Wegovy.",
            "banner_image": "https://g.foolcdn.com/editorial/images/758634/ozempic.jpg",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.796627"
                }
            ],
            "overall_sentiment_score": 0.004838,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "NVO",
                    "relevance_score": "0.820009",
                    "ticker_sentiment_score": "0.101886",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "These Are the 3 Hottest Biopharma Trends of 2024. Should You Invest?",
            "url": "https://www.fool.com/investing/2023/12/18/these-are-the-3-hottest-biopharma-trends-of-2024/",
            "time_published": "20231218T141500",
            "authors": [
                "Alex Carchidi"
            ],
            "summary": "2024 is going to be a sizzler in the biopharma sector.",
            "banner_image": "https://g.foolcdn.com/editorial/images/758306/business-people-and-doctors-talking-on-a-meeting-in-hospital.jpg",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.360215"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.5"
                }
            ],
            "overall_sentiment_score": 0.216785,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "NVDA",
                    "relevance_score": "0.049424",
                    "ticker_sentiment_score": "0.1381",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AZN",
                    "relevance_score": "0.098659",
                    "ticker_sentiment_score": "0.04645",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.147516",
                    "ticker_sentiment_score": "0.224328",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "LLY",
                    "relevance_score": "0.147516",
                    "ticker_sentiment_score": "0.051851",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "GPCR",
                    "relevance_score": "0.049424",
                    "ticker_sentiment_score": "0.088711",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "RXRX",
                    "relevance_score": "0.098659",
                    "ticker_sentiment_score": "0.147487",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "SDGR",
                    "relevance_score": "0.098659",
                    "ticker_sentiment_score": "0.147487",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "ABBV",
                    "relevance_score": "0.049424",
                    "ticker_sentiment_score": "0.043511",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "PFE",
                    "relevance_score": "0.098659",
                    "ticker_sentiment_score": "0.04645",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "BMY",
                    "relevance_score": "0.049424",
                    "ticker_sentiment_score": "0.043511",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "5 Big Drug Stocks That May Continue to Outperform in 2024",
            "url": "https://www.zacks.com/stock/news/2199316/5-big-drug-stocks-that-may-continue-to-outperform-in-2024",
            "time_published": "20231218T135400",
            "authors": [
                "Kinjel Shah"
            ],
            "summary": "Novo Nordisk (NVO), Eli Lilly (LLY), Vertex Pharmaceuticals (VRTX), Regeneron (REGN) and GSK (GSK) have been performing well this year. These stocks are poised to keep the momentum alive in 2024.",
            "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/6e/37920.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Economy - Monetary",
                    "relevance_score": "0.158519"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.980922"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.890401"
                },
                {
                    "topic": "Mergers & Acquisitions",
                    "relevance_score": "0.451494"
                }
            ],
            "overall_sentiment_score": 0.200783,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.184775",
                    "ticker_sentiment_score": "0.189145",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "VRTX",
                    "relevance_score": "0.046588",
                    "ticker_sentiment_score": "0.141465",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "GSK",
                    "relevance_score": "0.139131",
                    "ticker_sentiment_score": "0.152648",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.184775",
                    "ticker_sentiment_score": "0.155351",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "SNY",
                    "relevance_score": "0.023304",
                    "ticker_sentiment_score": "0.021882",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "As 2023 Comes To A Close And Updates Are Expected From Many Companies, Are These Three Unique Biotech Names On Your Watchlist? - Ginkgo Bioworks Holdings  ( NYSE:DNA ) , Eli Lilly  ( NYSE:LLY ) ",
            "url": "https://www.benzinga.com/general/biotech/23/12/36281714/as-2023-comes-to-a-close-and-updates-are-expected-from-many-companies-are-these-three-unique-biot",
            "time_published": "20231218T134542",
            "authors": [
                "Meg Flippin"
            ],
            "summary": "Biotech stocks have had a tough run in 2023 so far. As of early November, the iShares Biotechnology ETF ( IBB ) was down 7.5% while the S&P 500 was up more than 14%. But that doesn't mean investors should count them out.",
            "banner_image": "https://cdn.benzinga.com/files/images/story/2023/12/18/screenshot_2023-12-18_at_7.31.58_pm.png?width=1200&height=800&fit=crop",
            "source": "Benzinga",
            "category_within_source": "General",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.158519"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.650727"
                }
            ],
            "overall_sentiment_score": 0.139724,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.195419",
                    "ticker_sentiment_score": "0.080088",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "DNA",
                    "relevance_score": "0.098456",
                    "ticker_sentiment_score": "0.135255",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.098456",
                    "ticker_sentiment_score": "0.214798",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "PFE",
                    "relevance_score": "0.098456",
                    "ticker_sentiment_score": "0.214798",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Novo Nordisk A/S - share repurchase programme",
            "url": "https://www.globenewswire.com/news-release/2023/12/18/2797860/0/en/Novo-Nordisk-A-S-share-repurchase-programme.html",
            "time_published": "20231218T133700",
            "authors": [
                "Novo Nordisk A/S"
            ],
            "summary": "Bagsvrd, Denmark, 18 December 2023 - On 6 November 2023, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 ( MAR ) and the Commission Delegated Regulation ( EU ) 2016/1052 of 8 March ...",
            "banner_image": "https://ml-eu.globenewswire.com/Resource/Download/18c2fb08-e2c1-4a52-90dd-5c0f18213eb6",
            "source": "GlobeNewswire",
            "category_within_source": "n/a",
            "source_domain": "www.globenewswire.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.360215"
                }
            ],
            "overall_sentiment_score": 0.122936,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "GOOG",
                    "relevance_score": "0.122269",
                    "ticker_sentiment_score": "0.045242",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "META",
                    "relevance_score": "0.122269",
                    "ticker_sentiment_score": "0.045242",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.781591",
                    "ticker_sentiment_score": "0.195779",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Fake Wegovy: Pharma Giant Novo Nordisk Reportedly Steps Up Efforts Tackling Illegal Weight Loss Drugs Sold Online",
            "url": "https://www.forbes.com/sites/roberthart/2023/12/18/fake-wegovy-pharma-giant-novo-nordisk-reportedly-steps-up-efforts-tackling-illegal-weight-loss-drugs-sold-online/",
            "time_published": "20231218T130207",
            "authors": [
                "Robert Hart"
            ],
            "summary": "One of India's leading online marketplaces is working with pharma giant Novo Nordisk to tackle illegal sales of popular weight loss drug Wegovy, Reuters reported Monday, as its soaring popularity and strictly limited supply fosters a growing market for potentially dangerous fakes.",
            "banner_image": "https://imageio.forbes.com/specials-images/imageserve/654e47843345c024866cae6c/0x0.jpg?format=jpg&crop=5200,2927,x0,y269,safe&height=900&width=1600&fit=bounds",
            "source": "Forbes",
            "category_within_source": "n/a",
            "source_domain": "www.forbes.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": -0.117014,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "NVO",
                    "relevance_score": "0.187463",
                    "ticker_sentiment_score": "0.004772",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "5 Non-U.S. Stocks to Buy as Wall Street Fires on All Cylinders",
            "url": "https://www.zacks.com/stock/news/2199250/5-non-us-stocks-to-buy-as-wall-street-fires-on-all-cylinders",
            "time_published": "20231218T130000",
            "authors": [
                "Nalak Das"
            ],
            "summary": "We have selected five high-flying non-U.S. companies that have strong potential for 2024. These are: NVO, NTES, TM, PDD, STLA.",
            "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/42/1917.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Economy - Monetary",
                    "relevance_score": "0.682689"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.999941"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.233566,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "NTES",
                    "relevance_score": "0.21336",
                    "ticker_sentiment_score": "0.2428",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "PDD",
                    "relevance_score": "0.21336",
                    "ticker_sentiment_score": "0.23642",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "TM",
                    "relevance_score": "0.281827",
                    "ticker_sentiment_score": "0.240088",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.21336",
                    "ticker_sentiment_score": "0.261868",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "25% of Warren Buffett's Secret Portfolio Is Invested in These 3 ETFs. Here's Why They're Great Picks for 2024.",
            "url": "https://www.fool.com/investing/2023/12/18/warren-buffetts-secret-portfolio-invested-etfs/",
            "time_published": "20231218T110700",
            "authors": [
                "Keith Speights"
            ],
            "summary": "Buffett didn't personally pick these ETFs. But all three could make him money in the new year.",
            "banner_image": "https://g.foolcdn.com/editorial/images/758309/etf-board-and-person.jpg",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Economy - Monetary",
                    "relevance_score": "0.451494"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.5"
                }
            ],
            "overall_sentiment_score": 0.259993,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "SCHW",
                    "relevance_score": "0.06179",
                    "ticker_sentiment_score": "0.07223",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NSRGF",
                    "relevance_score": "0.06179",
                    "ticker_sentiment_score": "0.037001",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.06179",
                    "ticker_sentiment_score": "0.037001",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "IndiaMART is working with Novo Nordisk to halt illegal Wegovy sales",
            "url": "https://www.moneycontrol.com/news/business/indiamart-is-working-with-novo-nordisk-to-halt-illegal-wegovy-sales-11917991.html",
            "time_published": "20231218T012922",
            "authors": [],
            "summary": "The drugmaker's India legal team held discussions with IndiaMART's top executives to develop a \"framework\" for regularly alerting the online marketplace about listings by counterfeiters in an effort to curtail illegal sales, the source said on condition of anonymity.",
            "banner_image": "https://images.moneycontrol.com/static-mcnews/2023/12/CrazyCock-1.jpg?impolicy=website&width=168&height=118",
            "source": "Money Control",
            "category_within_source": "Business",
            "source_domain": "www.moneycontrol.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.055288,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "NVO",
                    "relevance_score": "0.054983",
                    "ticker_sentiment_score": "0.008",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "If You Had Invested $10,000 in Novo Nordisk in 2018, This Is How Much You Would Have Today",
            "url": "https://www.fool.com/investing/2023/12/17/if-you-had-invested-10000-in-novo-nordisk-in-2018/",
            "time_published": "20231217T133000",
            "authors": [
                "David Jagielski"
            ],
            "summary": "Is it too late to invest in this fast-growing pharmaceutical company?",
            "banner_image": "https://g.foolcdn.com/editorial/images/757822/investor-looking-at-stocks-on-a-tablet.jpg",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.650727"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.54554"
                }
            ],
            "overall_sentiment_score": 0.28249,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "NVO",
                    "relevance_score": "0.692191",
                    "ticker_sentiment_score": "0.36829",
                    "ticker_sentiment_label": "Bullish"
                }
            ]
        },
        {
            "title": "The weight loss drug boom isn't over yet - here's what to expect in the year ahead",
            "url": "https://www.cnbc.com/2023/12/17/weight-loss-drugs-2024-expectations-for-wegovy-ozempic-zepbound.html",
            "time_published": "20231217T130001",
            "authors": [
                "Annika Kim Constantino"
            ],
            "summary": "2024 will be another big year for weight loss drugs, which soared in popularity despite hefty price tags, mixed insurance coverage and unpleasant side effects.",
            "banner_image": "https://image.cnbcfm.com/api/v1/image/107346441-1702395741776-gettyimages-1807240143-WEIGHT_LOSS_DRUGS.jpeg?v=1702458927&w=1920&h=1080",
            "source": "CNBC",
            "category_within_source": "Business",
            "source_domain": "www.cnbc.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.495866"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.5"
                }
            ],
            "overall_sentiment_score": 0.050321,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "BCS",
                    "relevance_score": "0.016564",
                    "ticker_sentiment_score": "0.005187",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "BAC",
                    "relevance_score": "0.016564",
                    "ticker_sentiment_score": "0.065627",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AZN",
                    "relevance_score": "0.033121",
                    "ticker_sentiment_score": "0.10225",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "JPM",
                    "relevance_score": "0.016564",
                    "ticker_sentiment_score": "-0.056181",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "MS",
                    "relevance_score": "0.016564",
                    "ticker_sentiment_score": "0.065627",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.306761",
                    "ticker_sentiment_score": "0.04074",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "ALT",
                    "relevance_score": "0.033121",
                    "ticker_sentiment_score": "-0.000946",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "GPCR",
                    "relevance_score": "0.016564",
                    "ticker_sentiment_score": "-0.094366",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "GS",
                    "relevance_score": "0.016564",
                    "ticker_sentiment_score": "-0.017151",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "PFE",
                    "relevance_score": "0.082677",
                    "ticker_sentiment_score": "0.014482",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "2023: the year of the weight-loss drug craze",
            "url": "https://theweek.com/health/2023-weight-loss-drug-craze",
            "time_published": "20231217T090624",
            "authors": [
                "The Week US",
                "Theara Coleman"
            ],
            "summary": "Weight-loss drugs have a shaky history. But this year, a new generation of medications showed surprising promise - and then took the world by storm. Drugs like Ozempic and Mounjaro existed as treatments for Type 2 diabetes long before 2023, but doctors found that these treatments were ...",
            "banner_image": "https://cdn.mos.cms.futurecdn.net/RqXGNZjRwvQvT8RkG8MHpE-415-80.jpg",
            "source": "The Week News",
            "category_within_source": "n/a",
            "source_domain": "theweek.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.5"
                }
            ],
            "overall_sentiment_score": -0.027076,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "NYT",
                    "relevance_score": "0.032251",
                    "ticker_sentiment_score": "-0.039444",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "WBD",
                    "relevance_score": "0.032251",
                    "ticker_sentiment_score": "0.01825",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "FRNWF",
                    "relevance_score": "0.032251",
                    "ticker_sentiment_score": "0.055122",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.032251",
                    "ticker_sentiment_score": "0.01825",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "WeightWatchers bets on weight-loss drugs with launch of new program",
            "url": "https://www.foxbusiness.com/lifestyle/weightwatchers-bets-on-weight-loss-drugs-launch-new-program",
            "time_published": "20231215T204300",
            "authors": [
                "Daniella Genovese"
            ],
            "summary": "WeightWatchers launched a new program Thursday that targets consumers who use the highly popular weight-loss-related medications, marking its latest attempt to revive the brand. It's called the WeightWatchers GLP-1 Program, and it offers \"tailored behavioral support for individuals on a GLP-1 ...",
            "banner_image": "https://cf-images.us-east-1.prod.boltdns.net/v1/static/854081161001/5cf773d9-001d-45c3-9837-28c8fdbc5ff6/dfef189c-179a-4ba4-bf7c-df0deb291540/1280x720/match/image.jpg",
            "source": "Fox Business News",
            "category_within_source": "n/a",
            "source_domain": "www.foxbusiness.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.714479"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.29403,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "NVO",
                    "relevance_score": "0.095517",
                    "ticker_sentiment_score": "0.237591",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Weight-Loss Drug Gold Rush Gets Larger As New Player Fractyl Health Files For $100M IPO - Renaissance IPO ETF  ( ARCA:IPO ) , Renaissance Capital Greenwich Fund  ( ARCA:IPOS ) ",
            "url": "https://www.benzinga.com/general/biotech/23/12/36262799/weight-loss-drug-gold-rush-gets-larger-as-new-player-fractyl-health-files-for-100m-ipo",
            "time_published": "20231215T193923",
            "authors": [
                "Vandana Singh"
            ],
            "summary": "Fractyl Health, developing procedural and gene therapies for type 2 diabetes and obesity, filed an S-1 filing with the SEC on Thursday to raise up to $100 million in an initial public offering. Fractyl Health is a metabolic therapeutics company focused on new approaches for metabolic diseases, ...",
            "banner_image": "https://cdn.benzinga.com/files/images/story/2023/12/15/weight-loss-photo_by_vidmir_rais_via_pixabay.jpg?width=1200&height=800&fit=crop",
            "source": "Benzinga",
            "category_within_source": "General",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "IPO",
                    "relevance_score": "0.310843"
                }
            ],
            "overall_sentiment_score": 0.035393,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "NVO",
                    "relevance_score": "0.246582",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Has Arvinas  ( ARVN )  Outpaced Other Medical Stocks This Year?",
            "url": "https://www.zacks.com/stock/news/2198664/has-arvinas-arvn-outpaced-other-medical-stocks-this-year",
            "time_published": "20231215T144009",
            "authors": [
                "Zacks Equity Research"
            ],
            "summary": "Here is how Arvinas, Inc. (ARVN) and Novo Nordisk (NVO) have performed compared to their sector so far this year.",
            "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default314.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.714479"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.214378"
                }
            ],
            "overall_sentiment_score": 0.219611,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "NVO",
                    "relevance_score": "0.395012",
                    "ticker_sentiment_score": "0.29546",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "ARVN",
                    "relevance_score": "0.755492",
                    "ticker_sentiment_score": "0.29968",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Alexandria Real Estate Equities, Inc. Announces Long-Term 165940 RSF, Full-Building Lease With Novo Nordisk for ... - PR Newswire",
            "url": "https://www.prnewswire.com/news-releases/alexandria-real-estate-equities-inc-announces-long-term-165-940-rsf-full-building-lease-with-novo-nordisk-for-rd-center-at-the-alexandria-center-for-life-science--waltham-mega-campus-in-greater-boston-302016208.html",
            "time_published": "20231215T133000",
            "authors": [],
            "summary": "Alexandria Real Estate Equities, Inc. Announces Long-Term 165940 RSF, Full-Building Lease With Novo Nordisk for ... PR ...",
            "banner_image": null,
            "source": "PR Newswire",
            "category_within_source": "n/a",
            "source_domain": "www.prnewswire.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Real Estate & Construction",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.214378"
                }
            ],
            "overall_sentiment_score": 0.448188,
            "overall_sentiment_label": "Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "ARE",
                    "relevance_score": "0.199037",
                    "ticker_sentiment_score": "0.305794",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "AGTEF",
                    "relevance_score": "0.199037",
                    "ticker_sentiment_score": "0.311736",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.13347",
                    "ticker_sentiment_score": "0.16451",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Are You Sure You Want an Ozempic Pill?",
            "url": "https://www.theatlantic.com/health/archive/2023/12/obesity-drugs-ozempic-pills-injections/676359/",
            "time_published": "20231214T224400",
            "authors": [
                "Yasmin Tayag"
            ],
            "summary": "Obesity-Drugs Are Becoming Pills. Is That Really Better? The Atlantic ...",
            "banner_image": "https://cdn.theatlantic.com/thumbor/Ndji5CJ7gsbSEBSF2FZ4sf3gqyI=/0x0:2000x1125/960x540/media/img/mt/2023/12/pill2_1/original.jpg",
            "source": "The Atlantic",
            "category_within_source": "n/a",
            "source_domain": "www.theatlantic.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.05018,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "NVO",
                    "relevance_score": "0.054732",
                    "ticker_sentiment_score": "0.039996",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "PFE",
                    "relevance_score": "0.082017",
                    "ticker_sentiment_score": "0.00624",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Marine Enzymes Market to increase by USD 54.62 million from 2023 to 2028, Advanced Enzyme Technologies Ltd., Air ... - PR Newswire",
            "url": "https://www.prnewswire.com/news-releases/marine-enzymes-market-to-increase-by-usd-54-62-million-from-2023-to-2028--advanced-enzyme-technologies-ltd-air-liquide-sa-antozyme-biotech-pvt-ltd-and-more-among-key-companies--technavio-302015291.html",
            "time_published": "20231214T223000",
            "authors": [],
            "summary": "Marine Enzymes Market to increase by USD 54.62 million from 2023 to 2028, Advanced Enzyme Technologies Ltd., Air ... PR ...",
            "banner_image": null,
            "source": "PR Newswire",
            "category_within_source": "n/a",
            "source_domain": "www.prnewswire.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.239929,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "AIQUF",
                    "relevance_score": "0.136113",
                    "ticker_sentiment_score": "0.096458",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVZMY",
                    "relevance_score": "0.068306",
                    "ticker_sentiment_score": "0.085534",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.068306",
                    "ticker_sentiment_score": "0.085534",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Centene  ( CNC )  Ties Up to Aid Its Marketplace Members in Chicago",
            "url": "https://www.zacks.com/stock/news/2198151/centene-cnc-ties-up-to-aid-its-marketplace-members-in-chicago",
            "time_published": "20231214T164900",
            "authors": [
                "Zacks Equity Research"
            ],
            "summary": "Centene's (CNC) product - Ambetter of Illinois - along with RUSH aim to provide improved access to quality healthcare services for CNC's members in Chicago, and thereby grow its Marketplace business.",
            "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/6e/2354.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.890401"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.333333"
                }
            ],
            "overall_sentiment_score": 0.275936,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "CNC",
                    "relevance_score": "0.340245",
                    "ticker_sentiment_score": "0.442376",
                    "ticker_sentiment_label": "Bullish"
                },
                {
                    "ticker": "AMPH",
                    "relevance_score": "0.149656",
                    "ticker_sentiment_score": "0.16114",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "ITGR",
                    "relevance_score": "0.198628",
                    "ticker_sentiment_score": "0.15529",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "HCSG",
                    "relevance_score": "0.050148",
                    "ticker_sentiment_score": "0.264443",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.149656",
                    "ticker_sentiment_score": "0.16114",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "FDA Updates Labels of Esperion's  ( ESPR )  Cholesterol-Lowering Drugs",
            "url": "https://www.zacks.com/stock/news/2198132/fda-updates-labels-of-esperions-espr-cholesterol-lowering-drugs",
            "time_published": "20231214T163300",
            "authors": [
                "Zacks Equity Research"
            ],
            "summary": "The label to Esperion's (ESPR) marketed drugs Nexletol and Nexlizet have been updated to include the treatment of primary hyperlipidemia as a qualifier for existing approved populations.",
            "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/21/594.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.9545"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.05725,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "ESPR",
                    "relevance_score": "0.205807",
                    "ticker_sentiment_score": "0.008116",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "SKXJF",
                    "relevance_score": "0.069294",
                    "ticker_sentiment_score": "0.161791",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "OCUP",
                    "relevance_score": "0.138066",
                    "ticker_sentiment_score": "0.054284",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "DSKYF",
                    "relevance_score": "0.069294",
                    "ticker_sentiment_score": "0.161791",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "GLPG",
                    "relevance_score": "0.398148",
                    "ticker_sentiment_score": "0.093095",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.205807",
                    "ticker_sentiment_score": "0.131113",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Poison centers see nearly 1,500% increase in calls related to injected weight-loss drugs as people accidentally overdose",
            "url": "https://www.cnn.com/2023/12/13/health/semaglutide-overdoses-wellness/index.html",
            "time_published": "20231214T160500",
            "authors": [
                "Brenda Goodman"
            ],
            "summary": "Poison control centers across the US say they are seeing a steep increase in calls related to semaglutide, an injected medication used for diabetes and weight loss, with some people reporting symptoms related to accidental overdoses.",
            "banner_image": "https://media.cnn.com/api/v1/images/stellar/prod/230725115252-emily-wright.jpg?c=16x9&q=h_144,w_256,c_fill",
            "source": "CNN",
            "category_within_source": "Markets",
            "source_domain": "www.cnn.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": -0.169364,
            "overall_sentiment_label": "Somewhat-Bearish",
            "ticker_sentiment": [
                {
                    "ticker": "WBD",
                    "relevance_score": "0.030292",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.060541",
                    "ticker_sentiment_score": "-0.102138",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Ozempic Isn't the Best Weight-Loss Treatment Anymore. Here's Why That Shouldn't Matter to Novo Nordisk Investors.",
            "url": "https://www.fool.com/investing/2023/12/14/ozempic-isnt-the-best-weight-loss-treatment-anymor/",
            "time_published": "20231214T141000",
            "authors": [
                "David Jagielski"
            ],
            "summary": "Investors shouldn't be quick to discount Novo Nordisk's long-term potential.",
            "banner_image": "https://g.foolcdn.com/editorial/images/757809/doctor-discussing-a-report-with-people.jpg",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.161647"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.310843"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.5"
                }
            ],
            "overall_sentiment_score": 0.04371,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "GS",
                    "relevance_score": "0.061631",
                    "ticker_sentiment_score": "-0.067078",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "LLY",
                    "relevance_score": "0.24289",
                    "ticker_sentiment_score": "0.169559",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.463792",
                    "ticker_sentiment_score": "0.170344",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Alkermes plc Announces Agreement to Sell Athlone, Ireland Facility to Novo Nordisk",
            "url": "https://www.prnewswire.com/news-releases/alkermes-plc-announces-agreement-to-sell-athlone-ireland-facility-to-novo-nordisk-302014818.html",
            "time_published": "20231214T110500",
            "authors": [
                "Alkermes plc"
            ],
            "summary": "DUBLIN, Dec. 14, 2023 /PRNewswire/ -- Alkermes plc ( Nasdaq: ALKS ) today announced that it has entered into a definitive agreement to sell its development and manufacturing facility in Athlone, Ireland to Novo Nordisk, a leading global healthcare company.",
            "banner_image": "https://mma.prnewswire.com/media/616416/Alkermes_plc_Logo.jpg?p=facebook",
            "source": "PR Newswire",
            "category_within_source": "n/a",
            "source_domain": "www.prnewswire.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.360215"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.495866"
                }
            ],
            "overall_sentiment_score": 0.138461,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "ALKS",
                    "relevance_score": "0.586747",
                    "ticker_sentiment_score": "0.385197",
                    "ticker_sentiment_label": "Bullish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.256538",
                    "ticker_sentiment_score": "0.141416",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "People say weight-loss drugs 'stop working' - here's what we know about the 'Ozempic plateau' and how to avoid it",
            "url": "https://www.businessinsider.com/why-do-weight-loss-drugs-stop-working-ozempic-plateau-explained-2023-12",
            "time_published": "20231213T200800",
            "authors": [
                "Hilary Brueck"
            ],
            "summary": "Why do weight loss drugs stop working? Ozempic plateau explained - Business Insider ...",
            "banner_image": null,
            "source": "Business Insider",
            "category_within_source": "GoogleRSS",
            "source_domain": "www.businessinsider.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.004848,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "NVO",
                    "relevance_score": "0.041682",
                    "ticker_sentiment_score": "0.104445",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Obesity Drugs: Employers Embrace Virtual Healthcare to Manage Surging Costs - Novo Nordisk  ( NYSE:NVO ) , Eli Lilly  ( NYSE:LLY ) ",
            "url": "https://www.benzinga.com/general/biotech/23/12/36219440/obesity-drugs-employers-embrace-virtual-healthcare-to-manage-surging-costs",
            "time_published": "20231213T182849",
            "authors": [
                "Vandana Singh"
            ],
            "summary": "U.S. employers grappling with mounting expenses linked to covering obesity drugs like Novo Nordisk A/S's NVO Wegovy and Eli Lilly And Co's LLY Zepbound are increasingly turning to virtual healthcare providers such as Teladoc Health Inc TDOC to administer weight-loss management initiatives.",
            "banner_image": "https://cdn.benzinga.com/files/images/story/2023/12/13/weight_loss-photo_by_tumisu_from_pixabay.jpg?width=1200&height=800&fit=crop",
            "source": "Benzinga",
            "category_within_source": "General",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Real Estate & Construction",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.333333"
                }
            ],
            "overall_sentiment_score": 0.238247,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.223866",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "FBIN",
                    "relevance_score": "0.223866",
                    "ticker_sentiment_score": "0.37702",
                    "ticker_sentiment_label": "Bullish"
                },
                {
                    "ticker": "HLT",
                    "relevance_score": "0.223866",
                    "ticker_sentiment_score": "0.37702",
                    "ticker_sentiment_label": "Bullish"
                },
                {
                    "ticker": "TDOC",
                    "relevance_score": "0.223866",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.223866",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "BA",
                    "relevance_score": "0.223866",
                    "ticker_sentiment_score": "0.37702",
                    "ticker_sentiment_label": "Bullish"
                }
            ]
        },
        {
            "title": "Eli Lilly will be the first trillion-dollar drug company in history, billionaire investor Ken Langone says",
            "url": "https://markets.businessinsider.com/news/stocks/eli-lilly-stock-diabetes-ozempic-wegovy-weight-loss-drug-pharma-2023-12",
            "time_published": "20231213T174000",
            "authors": [
                "Aruni Soni"
            ],
            "summary": "Eli Lilly Will Be the First Trillion-Dollar Drug Company: Ken Langone - Markets Insider ...",
            "banner_image": null,
            "source": "Business Insider",
            "category_within_source": "GoogleRSS",
            "source_domain": "markets.businessinsider.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Retail & Wholesale",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.161647"
                }
            ],
            "overall_sentiment_score": 0.144091,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "HD",
                    "relevance_score": "0.124809",
                    "ticker_sentiment_score": "0.146535",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.124809",
                    "ticker_sentiment_score": "-0.108254",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "PFE",
                    "relevance_score": "0.124809",
                    "ticker_sentiment_score": "-0.142072",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.124809",
                    "ticker_sentiment_score": "0.100148",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Nvidia, Disney and Tesla are among 2023's buzziest stocks. Can they continue to sizzle in 2024?",
            "url": "https://www.marketwatch.com/story/nvidia-disney-and-tesla-are-among-2023s-buzziest-stocks-can-they-continue-to-sizzle-in-2024-bcea3881",
            "time_published": "20231213T172800",
            "authors": [
                "",
                "Ciara Linnane",
                "Emily Bary"
            ],
            "summary": "Here's a look at what MarketWatch staffers and readers consider to be 2023's most talked-about stocks - and the key issues that will drive their performances in the year to come.",
            "banner_image": "https://images.mktw.net/im-882031?width=700&height=392",
            "source": "MarketWatch",
            "category_within_source": "Top Stories",
            "source_domain": "www.marketwatch.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Blockchain",
                    "relevance_score": "0.451494"
                },
                {
                    "topic": "Retail & Wholesale",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.999976"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.108179"
                }
            ],
            "overall_sentiment_score": 0.146293,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "TGT",
                    "relevance_score": "0.043147",
                    "ticker_sentiment_score": "0.105782",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "WW",
                    "relevance_score": "0.043147",
                    "ticker_sentiment_score": "0.146279",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "GOOG",
                    "relevance_score": "0.021581",
                    "ticker_sentiment_score": "0.079279",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "META",
                    "relevance_score": "0.064681",
                    "ticker_sentiment_score": "0.182753",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NVDA",
                    "relevance_score": "0.171333",
                    "ticker_sentiment_score": "0.13932",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "TAP",
                    "relevance_score": "0.043147",
                    "ticker_sentiment_score": "-0.102156",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.043147",
                    "ticker_sentiment_score": "0.200728",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "COIN",
                    "relevance_score": "0.107591",
                    "ticker_sentiment_score": "0.038125",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "BUD",
                    "relevance_score": "0.043147",
                    "ticker_sentiment_score": "-0.041962",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "MSFT",
                    "relevance_score": "0.086167",
                    "ticker_sentiment_score": "0.089536",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "TSLA",
                    "relevance_score": "0.128937",
                    "ticker_sentiment_score": "0.067554",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AMD",
                    "relevance_score": "0.043147",
                    "ticker_sentiment_score": "0.021957",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "LLY",
                    "relevance_score": "0.064681",
                    "ticker_sentiment_score": "0.203605",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "GME",
                    "relevance_score": "0.086167",
                    "ticker_sentiment_score": "0.092222",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Pfizer Stock Sinks To 10-Year Low-Why Investors Have Soured On Covid-Era Giant",
            "url": "https://www.forbes.com/sites/dereksaul/2023/12/13/pfizer-stock-sinks-to-10-year-low-why-investors-have-soured-on-covid-era-giant/",
            "time_published": "20231213T143823",
            "authors": [
                "Derek Saul"
            ],
            "summary": "Pfizer stock's struggles continued Wednesday, as shares of the healthcare titan dropped to their lowest level since before the Covid-19 pandemic, the latest dubious milestone for the battered stock that has failed to convert its vaccine boom into long-term sales growth.",
            "banner_image": "https://imageio.forbes.com/specials-images/imageserve/6579be819e8d6dd237334ba2/0x0.jpg?format=jpg&crop=1701,1134,x0,y0,safe&height=900&width=1600&fit=bounds",
            "source": "Forbes",
            "category_within_source": "n/a",
            "source_domain": "www.forbes.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.108179"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.214378"
                }
            ],
            "overall_sentiment_score": 0.002458,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "SGEN",
                    "relevance_score": "0.218817",
                    "ticker_sentiment_score": "0.051337",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "MRNA",
                    "relevance_score": "0.110462",
                    "ticker_sentiment_score": "0.033284",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.110462",
                    "ticker_sentiment_score": "0.033284",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "PFE",
                    "relevance_score": "0.66906",
                    "ticker_sentiment_score": "0.003816",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.110462",
                    "ticker_sentiment_score": "0.033284",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Is it a Good Idea to Buy Journey Medical  ( DERM )  Stock Now?",
            "url": "https://www.zacks.com/stock/news/2197201/is-it-a-good-idea-to-buy-journey-medical-derm-stock-now",
            "time_published": "20231213T130900",
            "authors": [
                "Zacks Equity Research"
            ],
            "summary": "Here, we discuss some reasons why investing in Journey Medical (DERM) stock now may turn out to be a prudent move.",
            "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/55/1135.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.972193"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.108179"
                }
            ],
            "overall_sentiment_score": 0.220808,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "AUPH",
                    "relevance_score": "0.416844",
                    "ticker_sentiment_score": "0.296081",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "DERM",
                    "relevance_score": "0.352557",
                    "ticker_sentiment_score": "0.261504",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.285526",
                    "ticker_sentiment_score": "0.060449",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "ALPN",
                    "relevance_score": "0.352557",
                    "ticker_sentiment_score": "0.235744",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "LifeMD's stock soars 13% as company and Medifast to create weight-management program that includes GLP-1 drugs",
            "url": "https://www.marketwatch.com/story/lifemds-stock-soars-9-5-on-news-company-is-teaming-up-with-medifast-to-create-weight-management-program-that-includes-glp-1-drugs-55f94875",
            "time_published": "20231213T130400",
            "authors": [
                "Ciara Linnane"
            ],
            "summary": "Medifast is scrapping its quarterly dividend to invest instead in a partnership with LifeMD and other growth initiatives.",
            "banner_image": "https://images.mktw.net/im-793547/social",
            "source": "MarketWatch",
            "category_within_source": "Top Stories",
            "source_domain": "www.marketwatch.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.214378"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.5"
                }
            ],
            "overall_sentiment_score": 0.316562,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.258351",
                    "ticker_sentiment_score": "-0.071206",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "LFMD",
                    "relevance_score": "0.490323",
                    "ticker_sentiment_score": "0.406103",
                    "ticker_sentiment_label": "Bullish"
                },
                {
                    "ticker": "MED",
                    "relevance_score": "0.490323",
                    "ticker_sentiment_score": "0.459716",
                    "ticker_sentiment_label": "Bullish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.258351",
                    "ticker_sentiment_score": "-0.071206",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "What FDA Approval Means For CRSP Stock",
            "url": "https://www.investors.com/news/technology/crsp-stock-what-fda-approval-means-for-future-of-medicine/",
            "time_published": "20231212T210300",
            "authors": [
                "Investor's Business Daily",
                "ALEXIS GARCIA"
            ],
            "summary": "CRSP Stock: What FDA's Historic Gene Editing Approval Means For The Future Of Medicine Investor's Business Daily ...",
            "banner_image": "https://www.investors.com/wp-content/uploads/2023/12/q8qy2w7S.jpg",
            "source": "Investors Business Daily",
            "category_within_source": "n/a",
            "source_domain": "www.investors.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.996023"
                }
            ],
            "overall_sentiment_score": 0.091212,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "VRTX",
                    "relevance_score": "0.133692",
                    "ticker_sentiment_score": "0.176462",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.02686",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Weight Loss Drugs' Trickle Down Effect - Insurer Restrictions Create Access Challenges For Diabetes Patients - Novo Nordisk  ( NYSE:NVO ) , Eli Lilly  ( NYSE:LLY ) ",
            "url": "https://www.benzinga.com/general/biotech/23/12/36201549/weight-loss-drugs-trickle-down-effect-insurer-restrictions-create-access-challenges-for-diabetes-",
            "time_published": "20231212T185330",
            "authors": [
                "Vandana Singh"
            ],
            "summary": "There is growing concern among some type 2 diabetes patients over challenges in obtaining reimbursement for medications like Novo Nordisk A/S's NVO Ozempic amid stricter health plan management by U.S. insurers.",
            "banner_image": "https://cdn.benzinga.com/files/images/story/2023/12/12/ozempic.png?width=1200&height=800&fit=crop",
            "source": "Benzinga",
            "category_within_source": "General",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": -0.081518,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.250386",
                    "ticker_sentiment_score": "-0.125536",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.250386",
                    "ticker_sentiment_score": "0.061569",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "LLY Down as Patients Regain Weight After Stopping Zepbound",
            "url": "https://www.zacks.com/stock/news/2196988/lly-down-as-patients-regain-weight-after-stopping-zepbound",
            "time_published": "20231212T181900",
            "authors": [
                "Zacks Equity Research"
            ],
            "summary": "Full results from a late-stage study show that patients who stopped taking Eli Lilly's (LLY) weight-loss drug for over a year slowly started to regain their lost weight.",
            "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/fc/588.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.155041,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.504646",
                    "ticker_sentiment_score": "0.199782",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "AZN",
                    "relevance_score": "0.266828",
                    "ticker_sentiment_score": "0.222446",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.266828",
                    "ticker_sentiment_score": "0.30101",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Moderna  ( MRNA ) , Merck Start 2nd Late-Study on Cancer Therapy",
            "url": "https://www.zacks.com/stock/news/2196987/moderna-mrna-merck-start-2nd-late-study-on-cancer-therapy",
            "time_published": "20231212T181700",
            "authors": [
                "Zacks Equity Research"
            ],
            "summary": "The second late-stage study will evaluate Moderna (MRNA)/Merck's investigational cancer combination therapy in certain lung cancer patients. A late-stage study in melanoma indication is ongoing.",
            "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/08/595.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.928139"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.102939,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "MRNA",
                    "relevance_score": "0.546745",
                    "ticker_sentiment_score": "0.030291",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.178021",
                    "ticker_sentiment_score": "0.126283",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "CTMX",
                    "relevance_score": "0.29234",
                    "ticker_sentiment_score": "0.075936",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Sanofi  ( SNY )  Terminates Pompe Disease Deal as FTC Objects",
            "url": "https://www.zacks.com/stock/news/2196713/sanofi-sny-terminates-pompe-disease-deal-as-ftc-objects",
            "time_published": "20231212T142000",
            "authors": [
                "Zacks Equity Research"
            ],
            "summary": "Sanofi (SNY) decides to end the licensing deal with Maze Therapeutics for MZE001, a phase II ready oral tablet for Pompe disease, due to the FTC's decision to block the deal.",
            "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/85/906.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.990678"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.161647"
                }
            ],
            "overall_sentiment_score": 0.048242,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "NVO",
                    "relevance_score": "0.20698",
                    "ticker_sentiment_score": "0.054815",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "CTMX",
                    "relevance_score": "0.273552",
                    "ticker_sentiment_score": "0.074509",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "SNY",
                    "relevance_score": "0.459624",
                    "ticker_sentiment_score": "-0.021088",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Pfizer's  ( PFE )  Hemophilia Candidate BLA Gets FDA Acceptance",
            "url": "https://www.zacks.com/stock/news/2196706/pfizers-pfe-hemophilia-candidate-bla-gets-fda-acceptance",
            "time_published": "20231212T141400",
            "authors": [
                "Zacks Equity Research"
            ],
            "summary": "The FDA decision on Pfizer's (PFE) BLA for marstacimab for hemophilia A and B is expected in the fourth quarter of 2024, while the European Commission's decision is expected in 2025.",
            "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/ab/2180.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": -0.050781,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "NVO",
                    "relevance_score": "0.222327",
                    "ticker_sentiment_score": "-0.188014",
                    "ticker_sentiment_label": "Somewhat-Bearish"
                },
                {
                    "ticker": "PFE",
                    "relevance_score": "0.378777",
                    "ticker_sentiment_score": "0.097796",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Better Growth Stock: Viking Therapeutics or Iovance Biotherapeutics?",
            "url": "https://www.fool.com/investing/2023/12/12/better-growth-stock-viking-therapeutics-or-iovance/",
            "time_published": "20231212T134500",
            "authors": [
                "George Budwell"
            ],
            "summary": "Both of these pharma stocks could be big winners. But one stock screens as a better buy from a risk standpoint.",
            "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F757942%2Fgrowth-stock.jpg&op=resize&w=700",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Economy - Monetary",
                    "relevance_score": "0.158519"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.214378"
                }
            ],
            "overall_sentiment_score": 0.143186,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.060388",
                    "ticker_sentiment_score": "0.120006",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "VKTX",
                    "relevance_score": "0.120431",
                    "ticker_sentiment_score": "0.050158",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "IOVA",
                    "relevance_score": "0.120431",
                    "ticker_sentiment_score": "0.050158",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AMGN",
                    "relevance_score": "0.060388",
                    "ticker_sentiment_score": "0.17028",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.060388",
                    "ticker_sentiment_score": "0.120006",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "PFE",
                    "relevance_score": "0.060388",
                    "ticker_sentiment_score": "0.17028",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "FOREX:GBP",
                    "relevance_score": "0.060388",
                    "ticker_sentiment_score": "-0.073154",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Tome Biosciences Launches with Over $200 Million in Funding to Advance Programmable Genomic Integration Platform",
            "url": "https://www.benzinga.com/pressreleases/23/12/g36194633/tome-biosciences-launches-with-over-200-million-in-funding-to-advance-programmable-genomic-integra",
            "time_published": "20231212T125700",
            "authors": [
                "Globe Newswire"
            ],
            "summary": "Technology, in-licensed from the Massachusetts Institute of Technology ( MIT ) , capable of inserting DNA sequences of any size into any programmed genomic location Potential to create curative cell and integrative gene therapies",
            "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
            "source": "Benzinga",
            "category_within_source": "News",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Mergers & Acquisitions",
                    "relevance_score": "0.214378"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.108179"
                }
            ],
            "overall_sentiment_score": 0.17131,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "BRKR",
                    "relevance_score": "0.042048",
                    "ticker_sentiment_score": "-0.012649",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "FUJIF",
                    "relevance_score": "0.042048",
                    "ticker_sentiment_score": "-0.012649",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.042048",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NTLA",
                    "relevance_score": "0.042048",
                    "ticker_sentiment_score": "0.046584",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Better Weight Loss Stock: Eli Lilly or Novo Nordisk?",
            "url": "https://www.fool.com/investing/2023/12/12/better-weight-loss-stock-eli-lilly-or-novo-nordisk/",
            "time_published": "20231212T123000",
            "authors": [
                "George Budwell"
            ],
            "summary": "Both of these pharma stocks have been top performers in 2023. One stock is the better long-term buy, however.",
            "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F757950%2Fgrowth-trend.jpg&op=resize&w=700",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.614606"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.918141"
                }
            ],
            "overall_sentiment_score": 0.223546,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.457274",
                    "ticker_sentiment_score": "0.31369",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.138066",
                    "ticker_sentiment_score": "0.338499",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "US diabetes patients face delays as insurers tighten Ozempic coverage",
            "url": "https://www.reuters.com/business/healthcare-pharmaceuticals/us-diabetes-patients-face-delays-insurers-tighten-ozempic-coverage-2023-12-12/",
            "time_published": "20231212T120300",
            "authors": [
                "Deena Beasley"
            ],
            "summary": "Boxes of Ozempic and Mounjaro, semaglutide and tirzepatide injection drugs used for treating type 2 diabetes and made by Novo Nordisk and Eli Lilly, is seen at a Rock Canyon Pharmacy in Provo, Utah, U.S. March 29, 2023. REUTERS/George Frey/File Photo Acquire Licensing Rights",
            "banner_image": "https://cloudfront-us-east-2.images.arcpublishing.com/reuters/MBGEX7ZUKZI6HA44NILLL65OC4.jpg",
            "source": "Reuters",
            "category_within_source": "Business",
            "source_domain": "www.reuters.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.5"
                }
            ],
            "overall_sentiment_score": -0.06162,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "JPM",
                    "relevance_score": "0.043898",
                    "ticker_sentiment_score": "0.010841",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.087663",
                    "ticker_sentiment_score": "-0.005165",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "UNH",
                    "relevance_score": "0.043898",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "3 Best Profitable Stocks to Invest in Using Net Income Ratio",
            "url": "https://www.zacks.com/stock/news/2196527/3-best-profitable-stocks-to-invest-in-using-net-income-ratio",
            "time_published": "20231212T105200",
            "authors": [
                "Tirthankar Chakraborty"
            ],
            "summary": "Perdoceo Education (PRDO), Novo Nordisk (NVO) and Merchants Bancorp (MBIN) have been selected as the top picks with a high net income ratio.",
            "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/de/2471.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.266143"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.998626"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.5"
                }
            ],
            "overall_sentiment_score": 0.428322,
            "overall_sentiment_label": "Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "PRDO",
                    "relevance_score": "0.271274",
                    "ticker_sentiment_score": "0.248331",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "MBIN",
                    "relevance_score": "0.271274",
                    "ticker_sentiment_score": "0.297411",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.271274",
                    "ticker_sentiment_score": "0.23878",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Patients Who Stopped Using Zepbound Experienced 'Substantial' Weight Regain, Eli Lily's Study Suggests",
            "url": "https://www.forbes.com/sites/tylerroush/2023/12/11/patients-who-stopped-using-zepbound-experienced-substantial-weight-regain-eli-lilys-study-suggests/",
            "time_published": "20231211T210024",
            "authors": [
                "Ty Roush"
            ],
            "summary": "Patients using Eli Lilly's weight-loss drug Zepbound experienced a \"substantial regain\" of lost weight after withdrawing from treatment, according to a study published Monday, the latest study indicating withdrawal from weight-loss drugs could cause patients to regain lost weight.",
            "banner_image": "https://imageio.forbes.com/specials-images/imageserve/65777802c4ac494164a68f3d/0x0.jpg?format=jpg&crop=3397,1910,x0,y149,safe&height=900&width=1600&fit=bounds",
            "source": "Forbes",
            "category_within_source": "n/a",
            "source_domain": "www.forbes.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": -0.024097,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "WBD",
                    "relevance_score": "0.085324",
                    "ticker_sentiment_score": "-0.029115",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.169676",
                    "ticker_sentiment_score": "0.070683",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "5 Reasons to be Bullish into 2024",
            "url": "https://www.zacks.com/commentary/2196396/5-reasons-to-be-bullish-into-2024",
            "time_published": "20231211T202400",
            "authors": [
                "Andrew Rocco"
            ],
            "summary": "Stock Strategist Andrew Rocco unveils 5 bullish undercurrents that will push stocks eve ...",
            "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/19/56953.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.25"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.25"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.25"
                },
                {
                    "topic": "Economy - Monetary",
                    "relevance_score": "0.576289"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.891286"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.25"
                },
                {
                    "topic": "Mergers & Acquisitions",
                    "relevance_score": "0.158519"
                }
            ],
            "overall_sentiment_score": 0.014647,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "IMGN",
                    "relevance_score": "0.102888",
                    "ticker_sentiment_score": "0.076104",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "META",
                    "relevance_score": "0.102888",
                    "ticker_sentiment_score": "0.068224",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVDA",
                    "relevance_score": "0.102888",
                    "ticker_sentiment_score": "0.068224",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "SBNY",
                    "relevance_score": "0.051551",
                    "ticker_sentiment_score": "-0.062076",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "FRC",
                    "relevance_score": "0.051551",
                    "ticker_sentiment_score": "-0.062076",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.102888",
                    "ticker_sentiment_score": "0.076104",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "What's Going On With Ozempic-Maker Novo Nordisk Stock? - Novo Nordisk  ( NYSE:NVO ) ",
            "url": "https://www.benzinga.com/news/23/12/36179029/whats-going-on-with-ozempic-maker-novo-nordisk-stock",
            "time_published": "20231211T191855",
            "authors": [
                "Erica Kollmann"
            ],
            "summary": "Novo Nordisk A/S NVO shares are moving Monday and the Ozempic-maker's stock has gained more than 40% year-to-date. Here's a look at what's going on:",
            "banner_image": "https://cdn.benzinga.com/files/images/story/2023/12/11/novo_nordisk_stock_nvo_shares_ozempic_wegovy_weight_loss.jpg?width=1200&height=800&fit=crop",
            "source": "Benzinga",
            "category_within_source": "News",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.161647"
                }
            ],
            "overall_sentiment_score": 0.169367,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "NVO",
                    "relevance_score": "0.704675",
                    "ticker_sentiment_score": "0.56167",
                    "ticker_sentiment_label": "Bullish"
                }
            ]
        },
        {
            "title": "Lilly Weighs On Novo After Unveiling A New Finding For Obesity Drugs",
            "url": "https://www.investors.com/news/technology/eli-lilly-stock-slumps-as-a-new-study-highlights-the-impact-of-stopping-weight-loss-drug/",
            "time_published": "20231211T170400",
            "authors": [
                "Investor's Business Daily",
                "ALLISON GATLIN"
            ],
            "summary": "Eli Lilly Stock Slumps As A New Study Highlights The Impact Of Stopping Weight-Loss Drug Investor's Business Daily ...",
            "banner_image": "https://www.investors.com/wp-content/uploads/2020/10/Stock-EliLilly-Lab01-company.jpg",
            "source": "Investors Business Daily",
            "category_within_source": "n/a",
            "source_domain": "www.investors.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.858979"
                }
            ],
            "overall_sentiment_score": 0.007233,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.434514",
                    "ticker_sentiment_score": "0.07433",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.181819",
                    "ticker_sentiment_score": "-0.131405",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Bristol Myers Squibb A Top Socially Responsible Dividend Stock With 4.8% Yield",
            "url": "https://www.forbes.com/sites/dividendchannel/2023/12/11/bristol-myers-squibb-a-top-socially-responsible-dividend-stock-with-48-yield/",
            "time_published": "20231211T162328",
            "authors": [
                "Dividend Channel"
            ],
            "summary": "Bristol Myers Squibb has been named a Top Socially Responsible Dividend Stock by Dividend Channel, signifying a stock with above-average ''DividendRank'' statistics including a strong 4.8% yield, as well as being recognized by prominent asset managers as being a socially responsible investment, ...",
            "banner_image": "https://imageio.forbes.com/specials-images/imageserve/657737552a7ade988c66b81e/0x0.jpg?format=jpg&height=900&width=1600&fit=bounds",
            "source": "Forbes",
            "category_within_source": "n/a",
            "source_domain": "www.forbes.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.905476"
                }
            ],
            "overall_sentiment_score": 0.280251,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "NVO",
                    "relevance_score": "0.154455",
                    "ticker_sentiment_score": "0.123994",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "BMY",
                    "relevance_score": "0.757528",
                    "ticker_sentiment_score": "0.444906",
                    "ticker_sentiment_label": "Bullish"
                }
            ]
        },
        {
            "title": "Swedish regulator asks doctors not to prescribe diabetes drugs for weight loss",
            "url": "https://www.reuters.com/business/healthcare-pharmaceuticals/swedish-regulator-asks-doctors-not-prescribe-diabetes-drugs-weight-loss-2023-12-11/",
            "time_published": "20231211T133800",
            "authors": [
                "Reuters"
            ],
            "summary": "Injection pens of Novo Nordisk's weight-loss drug Wegovy are shown in this photo illustration in Oslo, Norway, November 21, 2023. REUTERS/Victoria Klesty/Illustration/File Photo Acquire Licensing Rights",
            "banner_image": "https://cloudfront-us-east-2.images.arcpublishing.com/reuters/LMZH3JPL4RLNHBGR7QRYIMJU4Y.jpg",
            "source": "Reuters",
            "category_within_source": "Business",
            "source_domain": "www.reuters.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": -0.004787,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "NVO",
                    "relevance_score": "0.160633",
                    "ticker_sentiment_score": "0.096596",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Novo Nordisk A/S - share repurchase programme",
            "url": "https://www.globenewswire.com/news-release/2023/12/11/2793850/0/en/Novo-Nordisk-A-S-share-repurchase-programme.html",
            "time_published": "20231211T132700",
            "authors": [
                "Novo Nordisk A/S"
            ],
            "summary": "Bagsvrd, Denmark, 11 December 2023 - On 6 November 2023, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 ( MAR ) and the Commission Delegated Regulation ( EU ) 2016/1052 of 8 March ...",
            "banner_image": "https://ml-eu.globenewswire.com/Resource/Download/18c2fb08-e2c1-4a52-90dd-5c0f18213eb6",
            "source": "GlobeNewswire",
            "category_within_source": "n/a",
            "source_domain": "www.globenewswire.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.360215"
                }
            ],
            "overall_sentiment_score": 0.122927,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "GOOG",
                    "relevance_score": "0.122269",
                    "ticker_sentiment_score": "0.045242",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "META",
                    "relevance_score": "0.122269",
                    "ticker_sentiment_score": "0.045242",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.781591",
                    "ticker_sentiment_score": "0.195779",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Is iShares International Equity Factor ETF  ( INTF )  a Strong ETF Right Now?",
            "url": "https://www.zacks.com/stock/news/2195943/is-ishares-international-equity-factor-etf-intf-a-strong-etf-right-now",
            "time_published": "20231211T112007",
            "authors": [
                "Zacks Equity Research"
            ],
            "summary": "Smart Beta ETF report for ...",
            "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default305.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.333333"
                }
            ],
            "overall_sentiment_score": 0.197564,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "BLK",
                    "relevance_score": "0.060085",
                    "ticker_sentiment_score": "0.041997",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NSRGF",
                    "relevance_score": "0.060085",
                    "ticker_sentiment_score": "-0.02003",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.060085",
                    "ticker_sentiment_score": "-0.02003",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "ASML",
                    "relevance_score": "0.11983",
                    "ticker_sentiment_score": "-0.023205",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Is Pfizer Stock a Buy Now?",
            "url": "https://www.fool.com/investing/2023/12/09/is-pfizer-stock-a-buy-now/",
            "time_published": "20231209T121500",
            "authors": [
                "David Jagielski"
            ],
            "summary": "Pfizer's stock recently hit a new 52-week low as the bad news continues for the pharma giant.",
            "banner_image": "https://g.foolcdn.com/editorial/images/756932/businessman-with-a-chart-looking-at-his-computer.jpg",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.796627"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.962106"
                }
            ],
            "overall_sentiment_score": 0.024413,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "NVO",
                    "relevance_score": "0.060541",
                    "ticker_sentiment_score": "0.061091",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "PFE",
                    "relevance_score": "0.676525",
                    "ticker_sentiment_score": "0.068596",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "SGEN",
                    "relevance_score": "0.060541",
                    "ticker_sentiment_score": "0.045102",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Bernie Sanders To Take On Ozempic, Wegovy, Weight Loss Drugs: 'Could Be Helpful, But They're Not Going To Be Helpful If People Can't Afford Them' - Novo Nordisk  ( NYSE:NVO ) ",
            "url": "https://www.benzinga.com/general/biotech/23/12/36161067/bernie-sanders-to-take-on-ozempic-wegovy-weight-loss-drugs-could-be-helpful-but-theyre-not-going-",
            "time_published": "20231208T210741",
            "authors": [
                "Chris Katje"
            ],
            "summary": "Congressman Bernie Sanders ( I-Vt. ) has been known to tussle with public companies over their high prices or anticompetitive behavior, including pharmaceutical companies and their high costs. In his newest battle, Sanders is taking on the growing popularity of weight-loss drugs and diabetes ...",
            "banner_image": "https://cdn.benzinga.com/files/images/story/2023/BernieSanders-Ozempic-Shutterstock.png?width=1200&height=800&fit=crop",
            "source": "Benzinga",
            "category_within_source": "Trading",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.360215"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.089381,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.214937",
                    "ticker_sentiment_score": "0.010354",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "ALT",
                    "relevance_score": "0.144275",
                    "ticker_sentiment_score": "0.198951",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.28387",
                    "ticker_sentiment_score": "-0.081186",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "PFE",
                    "relevance_score": "0.144275",
                    "ticker_sentiment_score": "0.027719",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Merck's  ( MRK )  Keytruda-Lynparza Combo Fails Lung Cancer Study",
            "url": "https://www.zacks.com/stock/news/2195640/mercks-mrk-keytruda-lynparza-combo-fails-lung-cancer-study",
            "time_published": "20231208T164400",
            "authors": [
                "Zacks Equity Research"
            ],
            "summary": "After a late-stage study fails to show any improvement in its primary endpoints, Merck (MRK) decides to stop evaluating the Keytruda-Lynparza combination in metastatic squamous NSCLC.",
            "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/21/594.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.96136"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.062494,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "AZN",
                    "relevance_score": "0.24289",
                    "ticker_sentiment_score": "-0.094988",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.18343",
                    "ticker_sentiment_score": "0.129012",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "CTMX",
                    "relevance_score": "0.300946",
                    "ticker_sentiment_score": "0.077697",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Here's How Much You Would Have Made Owning Novo Nordisk Stock In The Last 10 Years - Novo Nordisk  ( NYSE:NVO ) ",
            "url": "https://www.benzinga.com/news/23/12/36154806/heres-how-much-you-would-have-made-owning-novo-nordisk-stock-in-the-last-10-years",
            "time_published": "20231208T153106",
            "authors": [
                "Benzinga Insights"
            ],
            "summary": "Novo Nordisk NVO has outperformed the market over the past 10 years by 8.65% on an annualized basis producing an average annual return of 18.6%. Currently, Novo Nordisk has a market capitalization of $431.96 billion.",
            "banner_image": "https://cdn.benzinga.com/files/images/story/2023/valuestock_image_0.jpeg?width=1200&height=800&fit=crop",
            "source": "Benzinga",
            "category_within_source": "Trading",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.108179"
                }
            ],
            "overall_sentiment_score": 0.160819,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "NVO",
                    "relevance_score": "0.980595",
                    "ticker_sentiment_score": "0.386944",
                    "ticker_sentiment_label": "Bullish"
                }
            ]
        },
        {
            "title": "Novo, Lilly rivals explore booming weight-loss drug market entry",
            "url": "https://www.reuters.com/business/healthcare-pharmaceuticals/novo-lilly-rivals-explore-booming-weight-loss-drug-market-entry-2023-12-08/",
            "time_published": "20231208T145800",
            "authors": [
                "Reuters"
            ],
            "summary": "[1/2] An Eli Lilly and Company pharmaceutical manufacturing plant is pictured at 50 ImClone Drive in Branchburg, New Jersey, March 5, 2021. REUTERS/Mike Segar Acquire Licensing Rights",
            "banner_image": "https://cloudfront-us-east-2.images.arcpublishing.com/reuters/SM4NXZJ3KNLUVFGCLYVI3X4SGU.jpg",
            "source": "Reuters",
            "category_within_source": "Business",
            "source_domain": "www.reuters.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.16254,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "AZN",
                    "relevance_score": "0.067347",
                    "ticker_sentiment_score": "0.107057",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.067347",
                    "ticker_sentiment_score": "0.041069",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "PFE",
                    "relevance_score": "0.067347",
                    "ticker_sentiment_score": "-0.05009",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Pfizer's Latest Ozempic Competitor Just Flopped  ( Again ) . Is the Stock Still a Buy?",
            "url": "https://www.fool.com/investing/2023/12/08/pfizers-latest-ozempic-competitor-flopped-again/",
            "time_published": "20231208T143000",
            "authors": [
                "Alex Carchidi"
            ],
            "summary": "It's already planning to get back on the horse and make another attempt.",
            "banner_image": "https://g.foolcdn.com/editorial/images/757218/chemist-team-looking-beaker-of-green-chemical.jpg",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.108179"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.158519"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.5"
                }
            ],
            "overall_sentiment_score": 0.086517,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "SGEN",
                    "relevance_score": "0.059194",
                    "ticker_sentiment_score": "0.126308",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "JPM",
                    "relevance_score": "0.059194",
                    "ticker_sentiment_score": "0.046988",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.059194",
                    "ticker_sentiment_score": "0.122365",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "PFE",
                    "relevance_score": "0.344074",
                    "ticker_sentiment_score": "0.168193",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Could Eli Lilly Beat Novo Nordisk in the Billion-Dollar Weight Loss Market?",
            "url": "https://www.fool.com/investing/2023/12/08/could-lilly-beat-novo-nordisk-in-weight-loss/",
            "time_published": "20231208T103000",
            "authors": [
                "Adria Cimino"
            ],
            "summary": "These drugs address a rapidly growing market.",
            "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F757481%2Fgettyimages-1292931102.jpg&op=resize&w=700",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.158519"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.5"
                }
            ],
            "overall_sentiment_score": 0.156735,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "GS",
                    "relevance_score": "0.052685",
                    "ticker_sentiment_score": "0.15863",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "LLY",
                    "relevance_score": "0.491255",
                    "ticker_sentiment_score": "0.187817",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.356317",
                    "ticker_sentiment_score": "0.135845",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Red Biotechnology Market to Reach $1,513.22 Billion, Globally, by 2030 at 10.7% CAGR: Coherent Market Insights",
            "url": "https://www.prnewswire.com/news-releases/red-biotechnology-market-to-reach-1-513-22-billion-globally-by-2030-at-10-7-cagr-coherent-market-insights-302009313.html",
            "time_published": "20231208T071400",
            "authors": [
                "Coherent Market Insights"
            ],
            "summary": "BURLINGAME, Calif., Dec. 8, 2023 /PRNewswire/ -- According to Coherent Market Insights, The global red biotechnology market was valued at US$ 742.80 Billion in 2023 and is forecast to reach a value of US$ 1,513.22 Billion by 2030 at a CAGR of 10.7% between 2023 and 2030.",
            "banner_image": "https://mma.prnewswire.com/media/902389/Coherent_Market_Insights_Logo.jpg?p=facebook",
            "source": "PR Newswire",
            "category_within_source": "n/a",
            "source_domain": "www.prnewswire.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.360215"
                }
            ],
            "overall_sentiment_score": 0.196644,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "BAYZF",
                    "relevance_score": "0.028833",
                    "ticker_sentiment_score": "0.001897",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.028833",
                    "ticker_sentiment_score": "0.001897",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.028833",
                    "ticker_sentiment_score": "0.001897",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "ALPMF",
                    "relevance_score": "0.028833",
                    "ticker_sentiment_score": "0.001897",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVS",
                    "relevance_score": "0.028833",
                    "ticker_sentiment_score": "0.001897",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "ABBV",
                    "relevance_score": "0.028833",
                    "ticker_sentiment_score": "0.001897",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AMGN",
                    "relevance_score": "0.028833",
                    "ticker_sentiment_score": "0.001897",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "PFE",
                    "relevance_score": "0.028833",
                    "ticker_sentiment_score": "0.001897",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "BMY",
                    "relevance_score": "0.028833",
                    "ticker_sentiment_score": "0.001897",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AZN",
                    "relevance_score": "0.028833",
                    "ticker_sentiment_score": "0.001897",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "GILD",
                    "relevance_score": "0.028833",
                    "ticker_sentiment_score": "0.001897",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "TEVA",
                    "relevance_score": "0.028833",
                    "ticker_sentiment_score": "0.001897",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "GSK",
                    "relevance_score": "0.028833",
                    "ticker_sentiment_score": "0.001897",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "BIIB",
                    "relevance_score": "0.028833",
                    "ticker_sentiment_score": "0.001897",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "SNY",
                    "relevance_score": "0.028833",
                    "ticker_sentiment_score": "0.001897",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "TAK",
                    "relevance_score": "0.028833",
                    "ticker_sentiment_score": "0.001897",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Pharvaris  ( PHVS )  Stock Up 18% on HAE Drug Meeting Study Goal",
            "url": "https://www.zacks.com/stock/news/2195115/pharvaris-phvs-stock-up-18-on-hae-drug-meeting-study-goal",
            "time_published": "20231207T201700",
            "authors": [
                "Zacks Equity Research"
            ],
            "summary": "Data from a mid-stage study shows that treatment with Pharvaris' (PHVS) investigational HAE drug reduced the monthly attack rate by 84.5%.",
            "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/21/594.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.682689"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.052481,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "BCRX",
                    "relevance_score": "0.123526",
                    "ticker_sentiment_score": "0.03462",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "PHVS",
                    "relevance_score": "0.515749",
                    "ticker_sentiment_score": "0.067918",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "IONS",
                    "relevance_score": "0.123526",
                    "ticker_sentiment_score": "-0.175935",
                    "ticker_sentiment_label": "Somewhat-Bearish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.184363",
                    "ticker_sentiment_score": "0.138235",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Sanofi  ( SNY )  Posts Upbeat Long-Term Outlook, Enhances R&D Focus",
            "url": "https://www.zacks.com/stock/news/2195113/sanofi-sny-posts-upbeat-long-term-outlook-enhances-rd-focus",
            "time_published": "20231207T201600",
            "authors": [
                "Zacks Equity Research"
            ],
            "summary": "Sanofi (SNY) aims to generate annual sales of over 10 billion euros by 2030, driven by recently launched and potential new products. It intends to enhance R&D focus to become a market leader in immunology.",
            "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/8d/2080.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.890401"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.214378"
                }
            ],
            "overall_sentiment_score": 0.206543,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "AZN",
                    "relevance_score": "0.184363",
                    "ticker_sentiment_score": "0.075391",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.184363",
                    "ticker_sentiment_score": "0.138235",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "SNY",
                    "relevance_score": "0.56296",
                    "ticker_sentiment_score": "0.273461",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Altimmune's stock pops as analysts see obesity-drug partnership potential",
            "url": "https://www.marketwatch.com/story/altimmune-shares-pop-as-analysts-see-obesity-drug-partnership-potential-524ea4f4",
            "time_published": "20231207T173300",
            "authors": [
                "Eleanor Laise"
            ],
            "summary": "Altimmune shares have jumped this week as analysts see potential for the company to find a partner for its experimental weight-loss drug.",
            "banner_image": "https://images.mktw.net/im-520633/social",
            "source": "MarketWatch",
            "category_within_source": "Top Stories",
            "source_domain": "www.marketwatch.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.5"
                }
            ],
            "overall_sentiment_score": 0.12606,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "EVR",
                    "relevance_score": "0.09439",
                    "ticker_sentiment_score": "-0.093546",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AZN",
                    "relevance_score": "0.187463",
                    "ticker_sentiment_score": "0.055818",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.187463",
                    "ticker_sentiment_score": "0.055818",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "LLY",
                    "relevance_score": "0.187463",
                    "ticker_sentiment_score": "0.055818",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "ALT",
                    "relevance_score": "0.593484",
                    "ticker_sentiment_score": "0.244327",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "GS",
                    "relevance_score": "0.09439",
                    "ticker_sentiment_score": "0.199794",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "PFE",
                    "relevance_score": "0.187463",
                    "ticker_sentiment_score": "0.023005",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Is It Worth Investing in Novo Nordisk  ( NVO )  Based on Wall Street's Bullish Views?",
            "url": "https://www.zacks.com/stock/news/2194748/is-it-worth-investing-in-novo-nordisk-nvo-based-on-wall-streets-bullish-views",
            "time_published": "20231207T143006",
            "authors": [
                "Zacks Equity Research"
            ],
            "summary": "According to the average brokerage recommendation (ABR), one should invest in Novo Nordisk (NVO). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic. Would it be worth investing in the stock?",
            "banner_image": "https://staticx-tuner.zacks.com/images/yesopchart/brokerage_bar/NVO_12072023.png",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.938238"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.503496"
                }
            ],
            "overall_sentiment_score": 0.300007,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "NVO",
                    "relevance_score": "0.359262",
                    "ticker_sentiment_score": "0.234851",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "AbbVie  ( ABBV )  to Acquire Cerevel Therapeutics  ( CERE )  for $8.7B",
            "url": "https://www.zacks.com/stock/news/2194568/abbvie-abbv-to-acquire-cerevel-therapeutics-cere-for-87b",
            "time_published": "20231207T103800",
            "authors": [
                "Zacks Equity Research"
            ],
            "summary": "AbbVie (ABBV) offers to buy Cerevel Therapeutics (CERE) for $8.7 billion. The acquisition will strengthen AbbVie's neuroscience pipeline.",
            "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/66/1019.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.576289"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.365926"
                }
            ],
            "overall_sentiment_score": 0.179168,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "IMGN",
                    "relevance_score": "0.125789",
                    "ticker_sentiment_score": "0.005022",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "CERE",
                    "relevance_score": "0.187705",
                    "ticker_sentiment_score": "0.102679",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "ABBV",
                    "relevance_score": "0.616089",
                    "ticker_sentiment_score": "0.235896",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.187705",
                    "ticker_sentiment_score": "0.077098",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Zoetis Stock A Good Companion For Your Portfolio? Shares Rising",
            "url": "https://www.investors.com/news/technology/ibd-rating-upgrades-zoetis-flashes-improved-price-strength-2/",
            "time_published": "20231207T080000",
            "authors": [
                "INVESTOR'S BUSINESS DAILY",
                "JAMES DETAR",
                "Investor's Business Daily"
            ],
            "summary": "Zoetis Stock Good Companion For Portfolio? Investor's Business Daily ...",
            "banner_image": "https://www.investors.com/wp-content/uploads/2019/10/stock-Zoetis-04-shutter.jpg",
            "source": "Investors Business Daily",
            "category_within_source": "n/a",
            "source_domain": "www.investors.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "IPO",
                    "relevance_score": "0.158519"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.503496"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.917436"
                }
            ],
            "overall_sentiment_score": 0.255919,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "ZTS",
                    "relevance_score": "0.6809",
                    "ticker_sentiment_score": "0.33656",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.175221",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Walmart seems to have changed its view of weight-loss drugs",
            "url": "https://www.marketwatch.com/story/walmart-seems-to-have-changed-its-view-of-weight-loss-drugs-366d440a",
            "time_published": "20231206T191300",
            "authors": [
                "Ciara Linnane"
            ],
            "summary": "In October, the head of Walmart's U.S. business head has said the drugs were already causing customers to buy fewer groceries and cut back on those that are high in calories.",
            "banner_image": "https://images.mktw.net/im-354422/social",
            "source": "MarketWatch",
            "category_within_source": "Top Stories",
            "source_domain": "www.marketwatch.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.25"
                },
                {
                    "topic": "Retail & Wholesale",
                    "relevance_score": "0.25"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.360215"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.25"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.25"
                }
            ],
            "overall_sentiment_score": 0.0,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "GIS",
                    "relevance_score": "0.188928",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "KO",
                    "relevance_score": "0.188928",
                    "ticker_sentiment_score": "-0.170355",
                    "ticker_sentiment_label": "Somewhat-Bearish"
                },
                {
                    "ticker": "MS",
                    "relevance_score": "0.188928",
                    "ticker_sentiment_score": "-0.029478",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.188928",
                    "ticker_sentiment_score": "0.174794",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "LLY",
                    "relevance_score": "0.188928",
                    "ticker_sentiment_score": "0.174794",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "PEP",
                    "relevance_score": "0.188928",
                    "ticker_sentiment_score": "-0.170355",
                    "ticker_sentiment_label": "Somewhat-Bearish"
                },
                {
                    "ticker": "K",
                    "relevance_score": "0.188928",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "WMT",
                    "relevance_score": "0.188928",
                    "ticker_sentiment_score": "0.056142",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "J&J  ( JNJ )  Announces 2024 and Long-Term Financial Outlook",
            "url": "https://www.zacks.com/stock/news/2194292/jj-jnj-announces-2024-and-long-term-financial-outlook",
            "time_published": "20231206T162900",
            "authors": [
                "Zacks Equity Research"
            ],
            "summary": "J&J (JNJ) expects operational sales growth in the range of 5-6% in 2024, driven by both its Innovative Medicine and MedTech divisions.",
            "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/49/1007.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.161647"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.983605"
                },
                {
                    "topic": "Mergers & Acquisitions",
                    "relevance_score": "0.158519"
                }
            ],
            "overall_sentiment_score": 0.163494,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "KVUE",
                    "relevance_score": "0.174587",
                    "ticker_sentiment_score": "0.058625",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.174587",
                    "ticker_sentiment_score": "0.051207",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.286864",
                    "ticker_sentiment_score": "0.029825",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "JNJ CEO Signals No Rush Into Weight-Loss Drug Realm, Emphasizes Different Priorities - Johnson & Johnson  ( NYSE:JNJ ) ",
            "url": "https://www.benzinga.com/general/biotech/23/12/36114393/jnj-ceo-signals-no-rush-into-weight-loss-drug-realm-emphasizes-different-priorities",
            "time_published": "20231206T162336",
            "authors": [
                "Vandana Singh"
            ],
            "summary": "Johnson & Johnson JNJ has no immediate plans to venture into weight-loss drugs due to the existing competition saturation, as Chief Executive Officer Joaquin Duato highlighted. During the firm's investor day on Tuesday, Duato emphasized that the company's priorities lie in extensive expansion, ...",
            "banner_image": "https://cdn.benzinga.com/files/images/story/2023/12/06/jnjioffice3.jpg?width=1200&height=800&fit=crop",
            "source": "Benzinga",
            "category_within_source": "General",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.161647"
                }
            ],
            "overall_sentiment_score": 0.08561,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.27432",
                    "ticker_sentiment_score": "0.164786",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "ALT",
                    "relevance_score": "0.27432",
                    "ticker_sentiment_score": "0.337197",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.27432",
                    "ticker_sentiment_score": "0.164786",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "PFE",
                    "relevance_score": "0.27432",
                    "ticker_sentiment_score": "-0.148264",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.401331",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Pfizer  ( PFE ) , Arvinas Post Upbeat Data From Breast Cancer Study",
            "url": "https://www.zacks.com/stock/news/2194285/pfizer-pfe-arvinas-post-upbeat-data-from-breast-cancer-study",
            "time_published": "20231206T161800",
            "authors": [
                "Zacks Equity Research"
            ],
            "summary": "Interim data from an early-stage study shows that treatment with Pfizer (PFE)/Arvinas' (ARVN) breast cancer combination therapy demonstrates encouraging clinical activity in heavily pre-treated patients.",
            "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/21/594.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.890401"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.095793,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "CTMX",
                    "relevance_score": "0.318897",
                    "ticker_sentiment_score": "0.083659",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.194763",
                    "ticker_sentiment_score": "0.13483",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "PFE",
                    "relevance_score": "0.318897",
                    "ticker_sentiment_score": "0.002365",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "ARVN",
                    "relevance_score": "0.318897",
                    "ticker_sentiment_score": "-0.035797",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Obesity Drugs: Greater Weight Loss Linked to Prolonged Use of Novo Nordisk's Wegovy - Novo Nordisk  ( NYSE:NVO ) ",
            "url": "https://www.benzinga.com/general/biotech/23/12/36113639/obesity-drugs-greater-weight-loss-linked-to-prolonged-use-of-novo-nordisks-wegovy",
            "time_published": "20231206T145315",
            "authors": [
                "Vandana Singh"
            ],
            "summary": "A recent analysis of medical records and insurance claims data revealed that 40% of patients who received prescriptions for Novo Nordisk A/S's NVO obesity treatment drug Wegovy in 2021 or 2022 were still using it a year later.",
            "banner_image": "https://cdn.benzinga.com/files/images/story/2023/12/06/weight_loss-photo_by_tumisu_from_pixabay.jpg?width=1200&height=800&fit=crop",
            "source": "Benzinga",
            "category_within_source": "General",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": -0.034944,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "NVO",
                    "relevance_score": "0.436009",
                    "ticker_sentiment_score": "0.118925",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Altimmune open to partnerships, deals with drugmakers, says CEO",
            "url": "https://www.reuters.com/business/healthcare-pharmaceuticals/altimmune-open-partnerships-deals-with-drugmakers-says-ceo-2023-12-05/",
            "time_published": "20231205T182200",
            "authors": [
                "Pratik Jain",
                "Khushi Mandowara"
            ],
            "summary": "Dec 5 ( Reuters ) - Weight-loss drug developer Altimmune ( ALT.O ) is open to deals and collaborations with large drugmakers as it actively looks for partners to launch and develop its experimental obesity drug, CEO Vipin Garg told Reuters on Tuesday.",
            "banner_image": "https://www.reuters.com/pf/resources/images/reuters/reuters-default.webp?d=165",
            "source": "Reuters",
            "category_within_source": "Business",
            "source_domain": "www.reuters.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.108179"
                }
            ],
            "overall_sentiment_score": 0.163644,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "ALT",
                    "relevance_score": "0.28442",
                    "ticker_sentiment_score": "0.13484",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AZN",
                    "relevance_score": "0.096671",
                    "ticker_sentiment_score": "0.207373",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.096671",
                    "ticker_sentiment_score": "0.016513",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "PFE",
                    "relevance_score": "0.096671",
                    "ticker_sentiment_score": "-0.085243",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Alterity  ( ATHE )  Up on Preclinical Parkinson's Treatment Data",
            "url": "https://www.zacks.com/stock/news/2193796/alterity-athe-up-on-preclinical-parkinsons-treatment-data",
            "time_published": "20231205T181900",
            "authors": [
                "Zacks Equity Research"
            ],
            "summary": "Data from a preclinical study shows that treatment with Alterity's (ATHE) lead candidate improved motor performance and general function in monkeys with experimentally-induced Parkinson's disease.",
            "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/21/594.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.993781"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.12557,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "CTMX",
                    "relevance_score": "0.318074",
                    "ticker_sentiment_score": "0.078787",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "ATHE",
                    "relevance_score": "0.256989",
                    "ticker_sentiment_score": "0.143695",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.194242",
                    "ticker_sentiment_score": "0.149691",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "PBYI",
                    "relevance_score": "0.256989",
                    "ticker_sentiment_score": "0.114272",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "CRISPR  ( CRSP )  to Focus on Next-Generation CAR T Pipeline",
            "url": "https://www.zacks.com/stock/news/2193794/crispr-crsp-to-focus-on-next-generation-car-t-pipeline",
            "time_published": "20231205T181500",
            "authors": [
                "Zacks Equity Research"
            ],
            "summary": "Based on early data from ongoing clinical studies, CRISPR (CRSP) has decided to focus on the development of its next-generation CAR T pipeline and discontinue its first-generation CAR T candidates.",
            "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/e2/2838.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.938238"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.165226,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "VRTX",
                    "relevance_score": "0.094576",
                    "ticker_sentiment_score": "0.035504",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "CRSP",
                    "relevance_score": "0.233556",
                    "ticker_sentiment_score": "0.085501",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "CTMX",
                    "relevance_score": "0.233556",
                    "ticker_sentiment_score": "0.065273",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.141448",
                    "ticker_sentiment_score": "0.126402",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Goldman Sachs money manager digs into three themes for long-term growth",
            "url": "https://www.marketwatch.com/story/goldman-sachs-money-manager-digs-into-three-themes-for-long-term-growth-66add895",
            "time_published": "20231205T162700",
            "authors": [
                "Philip van Doorn"
            ],
            "summary": "Greg Tuorto explains how smaller companies can use a narrow focus to make a lot of money for investors.",
            "banner_image": "https://images.mktw.net/im-60177213/social",
            "source": "MarketWatch",
            "category_within_source": "Top Stories",
            "source_domain": "www.marketwatch.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.166667"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.166667"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.166667"
                },
                {
                    "topic": "IPO",
                    "relevance_score": "0.310843"
                },
                {
                    "topic": "Retail & Wholesale",
                    "relevance_score": "0.166667"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.99999"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.166667"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.77141"
                },
                {
                    "topic": "Real Estate & Construction",
                    "relevance_score": "0.166667"
                }
            ],
            "overall_sentiment_score": 0.141773,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "MTH",
                    "relevance_score": "0.057837",
                    "ticker_sentiment_score": "0.170998",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NVDA",
                    "relevance_score": "0.028937",
                    "ticker_sentiment_score": "0.164782",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "TENB",
                    "relevance_score": "0.08666",
                    "ticker_sentiment_score": "0.138103",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "WING",
                    "relevance_score": "0.057837",
                    "ticker_sentiment_score": "0.268032",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.057837",
                    "ticker_sentiment_score": "0.038038",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "GS",
                    "relevance_score": "0.08666",
                    "ticker_sentiment_score": "0.044149",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "MSFT",
                    "relevance_score": "0.028937",
                    "ticker_sentiment_score": "0.164782",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "SG",
                    "relevance_score": "0.057837",
                    "ticker_sentiment_score": "-0.200894",
                    "ticker_sentiment_label": "Somewhat-Bearish"
                },
                {
                    "ticker": "CAVA",
                    "relevance_score": "0.057837",
                    "ticker_sentiment_score": "0.140989",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "SHAK",
                    "relevance_score": "0.057837",
                    "ticker_sentiment_score": "-0.200894",
                    "ticker_sentiment_label": "Somewhat-Bearish"
                },
                {
                    "ticker": "IRTC",
                    "relevance_score": "0.057837",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "MORN",
                    "relevance_score": "0.028937",
                    "ticker_sentiment_score": "0.037486",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AXNX",
                    "relevance_score": "0.172301",
                    "ticker_sentiment_score": "0.103012",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "An EU wealth tax and the end of U.S. capitalism: One bank's 'outrageous' predictions for 2024",
            "url": "https://www.cnbc.com/2023/12/05/eu-wealth-tax-and-end-of-us-capitalism-saxos-outrageous-predictions.html",
            "time_published": "20231205T144111",
            "authors": [
                "Elliot Smith"
            ],
            "summary": "An EU wealth tax and the \"end of capitalism\" in the U.S. are just some of the \"outrageous predictions\" put forward by Saxo Bank in a report published Tuesday.",
            "banner_image": "https://image.cnbcfm.com/api/v1/image/107343086-17017726811701772678-32319130032-1080pnbcnews.jpg?v=1701772680&w=750&h=422&vtcrop=y",
            "source": "CNBC",
            "category_within_source": "Top News",
            "source_domain": "www.cnbc.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.25"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.25"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.25"
                },
                {
                    "topic": "Economy - Monetary",
                    "relevance_score": "0.682689"
                },
                {
                    "topic": "Economy - Fiscal",
                    "relevance_score": "0.158519"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.955357"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.25"
                }
            ],
            "overall_sentiment_score": 0.076069,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "MSFT",
                    "relevance_score": "0.034282",
                    "ticker_sentiment_score": "0.111554",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVDA",
                    "relevance_score": "0.034282",
                    "ticker_sentiment_score": "0.111554",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "TSLA",
                    "relevance_score": "0.034282",
                    "ticker_sentiment_score": "0.111554",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "JPM",
                    "relevance_score": "0.034282",
                    "ticker_sentiment_score": "-0.024255",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.068502",
                    "ticker_sentiment_score": "0.100337",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "FOREX:USD",
                    "relevance_score": "0.034282",
                    "ticker_sentiment_score": "-0.051416",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "CRYPTO:BTC",
                    "relevance_score": "0.034282",
                    "ticker_sentiment_score": "-0.036314",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "J&J's  ( JNJ )  Bladder Cancer Drug Gets FDA's Breakthrough Tag",
            "url": "https://www.zacks.com/stock/news/2193403/jjs-jnj-bladder-cancer-drug-gets-fdas-breakthrough-tag",
            "time_published": "20231205T124000",
            "authors": [
                "Zacks Equity Research"
            ],
            "summary": "FDA grants Breakthrough Therapy Designation to J&J's (JNJ) TAR-200 for high-risk non-muscle-invasive bladder cancer based on data from the phase IIb SunRISe-1 study.",
            "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/52/873.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.983605"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.161647"
                }
            ],
            "overall_sentiment_score": -0.044131,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "NVO",
                    "relevance_score": "0.229149",
                    "ticker_sentiment_score": "0.05945",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "CTMX",
                    "relevance_score": "0.302243",
                    "ticker_sentiment_score": "0.082988",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.302243",
                    "ticker_sentiment_score": "-0.111678",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "No more exercising? President RFK Jr.? Here's one bank's outrageous predictions for 2024",
            "url": "https://www.marketwatch.com/story/no-more-exercising-president-rfk-jr-heres-one-banks-outrageous-predictions-for-2024-1bc90579",
            "time_published": "20231205T104500",
            "authors": [
                "Steve Goldstein"
            ],
            "summary": "Denmark's Saxo Bank makes a tradition of making \"outrageous predictions,\" which every once in a while comes true ...",
            "banner_image": "https://images.mktw.net/im-23070502/social",
            "source": "MarketWatch",
            "category_within_source": "Top Stories",
            "source_domain": "www.marketwatch.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.538269"
                }
            ],
            "overall_sentiment_score": -0.089195,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.162255",
                    "ticker_sentiment_score": "0.053536",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.162255",
                    "ticker_sentiment_score": "0.053536",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "FOREX:JPY",
                    "relevance_score": "0.081552",
                    "ticker_sentiment_score": "0.011316",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Jim Cramer Highlights 'Transformational' Impact Of Weight Loss Drugs Like Ozempic: Focus Now On 'Potential Winners' From The Same Narrative - Novo Nordisk  ( NYSE:NVO ) , Eli Lilly  ( NYSE:LLY ) ",
            "url": "https://www.benzinga.com/news/23/12/36083857/jim-cramer-highlights-transformational-impact-of-weight-loss-drugs-like-ozempic-focus-now-on-potenti",
            "time_published": "20231205T012432",
            "authors": [
                "Benzinga Neuro"
            ],
            "summary": "What Happened: Jim Cramer outlined fresh investment prospects on Monday, revolving around the growing demand for GLP-1 drugs, typically administered for diabetes and obesity treatment. As reported by CNBC, investors initially expressed concerns about these drugs' market impact.",
            "banner_image": "https://cdn.benzinga.com/files/images/story/2023/Jim-Cramer-Photo-by-s-bukley-on-Shutters_1.jpeg?width=1200&height=800&fit=crop",
            "source": "Benzinga",
            "category_within_source": "News",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.161647"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Real Estate & Construction",
                    "relevance_score": "0.333333"
                }
            ],
            "overall_sentiment_score": 0.321611,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.356865",
                    "ticker_sentiment_score": "0.359113",
                    "ticker_sentiment_label": "Bullish"
                },
                {
                    "ticker": "J",
                    "relevance_score": "0.092213",
                    "ticker_sentiment_score": "0.172399",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "HRL",
                    "relevance_score": "0.092213",
                    "ticker_sentiment_score": "0.172399",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.356865",
                    "ticker_sentiment_score": "0.359113",
                    "ticker_sentiment_label": "Bullish"
                },
                {
                    "ticker": "TSN",
                    "relevance_score": "0.092213",
                    "ticker_sentiment_score": "0.172399",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Roche, Pfizer Race To Find Next Ozempic As Pharma Giants Hustle To Join Obesity Treatment Market - Tema Cardiovascular and Metabolic ETF  ( NASDAQ:HRTS ) , Altimmune  ( NASDAQ:ALT ) ",
            "url": "https://www.benzinga.com/markets/equities/23/12/36079945/roche-pfizer-race-to-find-next-ozempic-as-pharma-giants-hustle-to-join-obesity-treatment-market",
            "time_published": "20231204T212012",
            "authors": [
                "Neil Dennis"
            ],
            "summary": "How important it is to have the latest blockbuster in your product portfolio. The pharmaceuticals industry has displayed this over and again in recent years - getting a Covid vaccine to market during the pandemic, and now tackling the obesity epidemic.",
            "banner_image": "https://cdn.benzinga.com/files/images/story/2023/weight-loss-shutter2.jpeg?width=1200&height=800&fit=crop",
            "source": "Benzinga",
            "category_within_source": "General",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.614606"
                }
            ],
            "overall_sentiment_score": 0.072139,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.162802",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "ALT",
                    "relevance_score": "0.162802",
                    "ticker_sentiment_score": "0.267128",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.162802",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "PFE",
                    "relevance_score": "0.318897",
                    "ticker_sentiment_score": "-0.004677",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Roche Will Buy Obesity And Diabetes Drugmaker Carmot Therapeutics In $2.7 Billion Deal",
            "url": "https://www.forbes.com/sites/britneynguyen/2023/12/04/roche-will-buy-obesity-and-diabetes-drugmaker-carmot-therapeutics-in-27-billion-deal/",
            "time_published": "20231204T192410",
            "authors": [
                "Britney Nguyen"
            ],
            "summary": "Swiss pharmaceuticals company Roche agreed to acquire U.S.-based weight-loss drugmaker Carmot Therapeutics, which develops anti-obesity and diabetes drugs, for $2.7 million, according to a press release, as drug makers seek to challenge Novo Nordisk and Eli Lilly, which remain the dominant ...",
            "banner_image": "https://imageio.forbes.com/specials-images/imageserve/656e25a4ad16afaa37edede2/0x0.jpg?format=jpg&crop=1272,716,x0,y127,safe&height=900&width=1600&fit=bounds",
            "source": "Forbes",
            "category_within_source": "n/a",
            "source_domain": "www.forbes.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "IPO",
                    "relevance_score": "0.158519"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.5"
                }
            ],
            "overall_sentiment_score": 0.11584,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "AZN",
                    "relevance_score": "0.057628",
                    "ticker_sentiment_score": "0.013012",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.227538",
                    "ticker_sentiment_score": "0.02842",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "SGTX",
                    "relevance_score": "0.057628",
                    "ticker_sentiment_score": "0.013012",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Centene  ( CNC )  Wins Contract From Arizona's Medicaid Agency",
            "url": "https://www.zacks.com/stock/news/2193148/centene-cnc-wins-contract-from-arizonas-medicaid-agency",
            "time_published": "20231204T171300",
            "authors": [
                "Zacks Equity Research"
            ],
            "summary": "Centene's (CNC) Arizona subsidiary has been chosen by the AHCCCS to improve health outcomes for the state's ALTCS-E/PD members and further solidify statewide presence.",
            "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/6e/2354.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.96136"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.5"
                }
            ],
            "overall_sentiment_score": 0.327442,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "CNC",
                    "relevance_score": "0.378572",
                    "ticker_sentiment_score": "0.400547",
                    "ticker_sentiment_label": "Bullish"
                },
                {
                    "ticker": "AMPH",
                    "relevance_score": "0.242406",
                    "ticker_sentiment_score": "0.209763",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "IRMD",
                    "relevance_score": "0.146916",
                    "ticker_sentiment_score": "0.031865",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "HCSG",
                    "relevance_score": "0.049221",
                    "ticker_sentiment_score": "0.253224",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.146916",
                    "ticker_sentiment_score": "0.11025",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Roche  ( RHHBY )  to Acquire Obesity Drug Maker Carmot for $2.7B",
            "url": "https://www.zacks.com/stock/news/2193099/roche-rhhby-to-acquire-obesity-drug-maker-carmot-for-27b",
            "time_published": "20231204T165200",
            "authors": [
                "Zacks Equity Research"
            ],
            "summary": "Roche (RHHBY) aims to enter the promising and much-in-demand obesity drug market with the acquisition of Carmot Therapeutics, Inc. for $2.7 billion.",
            "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/c2/53795.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.108179"
                }
            ],
            "overall_sentiment_score": 0.151332,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "NVO",
                    "relevance_score": "0.212425",
                    "ticker_sentiment_score": "0.27225",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "PFE",
                    "relevance_score": "0.212425",
                    "ticker_sentiment_score": "-0.135965",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Altimmune  ( ALT )  Rises 83% on Successful Phase II Obesity Study",
            "url": "https://www.zacks.com/stock/news/2193078/altimmune-alt-rises-83-on-successful-phase-ii-obesity-study",
            "time_published": "20231204T163700",
            "authors": [
                "Zacks Equity Research"
            ],
            "summary": "Altimmune (ALT) reports positive top-line data from its 48-week phase II MOMENTUM study of obesity drug candidate, pemvidutide. The stock gains 83%.",
            "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/c8/39674.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.161647"
                }
            ],
            "overall_sentiment_score": 0.093656,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.177802",
                    "ticker_sentiment_score": "0.191896",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "ALT",
                    "relevance_score": "0.346884",
                    "ticker_sentiment_score": "-0.082228",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.221212",
                    "ticker_sentiment_score": "0.1681",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "PFE",
                    "relevance_score": "0.177802",
                    "ticker_sentiment_score": "0.03385",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "This 1 Surprising New Tailwind Is Lifting These 2 Evergreen Stocks",
            "url": "https://www.fool.com/investing/2023/12/04/this-1-surprising-new-tailwind-is-lifting-these-2/",
            "time_published": "20231204T152300",
            "authors": [
                "Alex Carchidi"
            ],
            "summary": "New growth drivers are helping to propel these reliable and steady businesses.",
            "banner_image": "https://g.foolcdn.com/editorial/images/756811/medical-staff-talk-with-management.jpg",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Retail & Wholesale",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.495866"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.108179"
                },
                {
                    "topic": "Real Estate & Construction",
                    "relevance_score": "0.333333"
                }
            ],
            "overall_sentiment_score": 0.161558,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "MCK",
                    "relevance_score": "0.22595",
                    "ticker_sentiment_score": "0.152349",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.114137",
                    "ticker_sentiment_score": "0.050731",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "COR",
                    "relevance_score": "0.280294",
                    "ticker_sentiment_score": "0.141367",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Roche enters obesity market with Carmot takeover but drugs may not be available until 2030",
            "url": "https://www.cnbc.com/2023/12/04/roche-enters-obesity-market-with-carmot-takeover.html",
            "time_published": "20231204T143713",
            "authors": [
                "Karen Gilchrist"
            ],
            "summary": "Roche is to acquire anti obesity drug developer Carmot Therapeutics, becoming the latest pharma company to enter the global weight-loss drugs market.",
            "banner_image": "https://image.cnbcfm.com/api/v1/image/107342556-1701698499762-gettyimages-1236831271-RAFAPRESS_26112021-2231.jpeg?v=1701698655&w=1920&h=1080",
            "source": "CNBC",
            "category_within_source": "Top News",
            "source_domain": "www.cnbc.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.190779,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "PTAIF",
                    "relevance_score": "0.076115",
                    "ticker_sentiment_score": "0.146621",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.151539",
                    "ticker_sentiment_score": "-0.036764",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "PFE",
                    "relevance_score": "0.076115",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Novo Nordisk A/S - share repurchase programme",
            "url": "https://www.globenewswire.com/news-release/2023/12/04/2789928/0/en/Novo-Nordisk-A-S-share-repurchase-programme.html",
            "time_published": "20231204T124200",
            "authors": [
                "Novo Nordisk A/S"
            ],
            "summary": "Bagsvrd, Denmark, 04 December 2023 - On 6 November 2023, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 ( MAR ) and the Commission Delegated Regulation ( EU ) 2016/1052 of 8 March ...",
            "banner_image": "https://ml-eu.globenewswire.com/Resource/Download/18c2fb08-e2c1-4a52-90dd-5c0f18213eb6",
            "source": "GlobeNewswire",
            "category_within_source": "n/a",
            "source_domain": "www.globenewswire.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.360215"
                }
            ],
            "overall_sentiment_score": 0.141508,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "GOOG",
                    "relevance_score": "0.122269",
                    "ticker_sentiment_score": "0.045242",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "META",
                    "relevance_score": "0.122269",
                    "ticker_sentiment_score": "0.045242",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.781591",
                    "ticker_sentiment_score": "0.230049",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Roche Joins Bandwagon To Challenge Novo Nordisk, Eli Lilly For Weight Loss Drugs - Roche Holding  ( OTC:RHHBF ) , Roche Holding  ( OTC:RHHVF ) , Roche Holding  ( OTC:RHHBY ) ",
            "url": "https://www.benzinga.com/general/biotech/23/12/36064233/roche-joins-bandwagon-to-challenge-novo-nordisk-eli-lilly-for-weight-loss-drugs",
            "time_published": "20231204T120428",
            "authors": [
                "Vandana Singh"
            ],
            "summary": "Roche Holding AG RHHBY has agreed to acquire a privately held obesity company Carmot Therapeutics, seeking to challenge the dominance of weight-loss drugs from Novo Nordisk A/S NVO and Eli Lilly And Co LLY.",
            "banner_image": "https://cdn.benzinga.com/files/images/story/2023/12/04/roche.png?width=1200&height=800&fit=crop",
            "source": "Benzinga",
            "category_within_source": "General",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.161647"
                }
            ],
            "overall_sentiment_score": 0.24333,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.21686",
                    "ticker_sentiment_score": "0.24258",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.21686",
                    "ticker_sentiment_score": "0.24258",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Is Invesco S&P International Developed Quality ETF  ( IDHQ )  a Strong ETF Right Now?",
            "url": "https://www.zacks.com/stock/news/2192721/is-invesco-sp-international-developed-quality-etf-idhq-a-strong-etf-right-now",
            "time_published": "20231204T112005",
            "authors": [
                "Zacks Equity Research"
            ],
            "summary": "Smart Beta ETF report for ...",
            "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default88.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.21937,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "IVZ",
                    "relevance_score": "0.172097",
                    "ticker_sentiment_score": "0.080245",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NSRGF",
                    "relevance_score": "0.057767",
                    "ticker_sentiment_score": "0.05496",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.057767",
                    "ticker_sentiment_score": "0.05496",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Roche strikes $3.1 billion deal to buy obesity-drug maker Carmot Therapeutics in race to rival Novo Nordisk's Ozempic",
            "url": "https://www.marketwatch.com/story/roche-strikes-3-1-billion-deal-to-buy-obesity-drug-maker-carmot-therapeutics-billion-in-race-to-rival-novo-nordisks-ozempic-6b88b8c9",
            "time_published": "20231204T104000",
            "authors": [
                "Louis Goss"
            ],
            "summary": "The race for weight-loss drugs stepped up Monday after Roche said it would buy obesity-drug developer Carmot Therapeutics for up to $3.1 billion.",
            "banner_image": "https://images.mktw.net/im-740245/social",
            "source": "MarketWatch",
            "category_within_source": "Top Stories",
            "source_domain": "www.marketwatch.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "IPO",
                    "relevance_score": "0.158519"
                },
                {
                    "topic": "Retail & Wholesale",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.360215"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.333333"
                }
            ],
            "overall_sentiment_score": 0.140301,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.175859",
                    "ticker_sentiment_score": "0.105946",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "BCS",
                    "relevance_score": "0.059049",
                    "ticker_sentiment_score": "0.201018",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "AZN",
                    "relevance_score": "0.175859",
                    "ticker_sentiment_score": "0.132332",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.232996",
                    "ticker_sentiment_score": "0.219072",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "PFE",
                    "relevance_score": "0.232996",
                    "ticker_sentiment_score": "-0.013105",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "WMT",
                    "relevance_score": "0.117774",
                    "ticker_sentiment_score": "-0.072874",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Pfizer  ( PFE )  Stock Down 5% as Obesity Drug Fails in Phase II",
            "url": "https://www.zacks.com/stock/news/2192689/pfizer-pfe-stock-down-5-as-obesity-drug-fails-in-phase-ii",
            "time_published": "20231204T103200",
            "authors": [
                "Zacks Equity Research"
            ],
            "summary": "The failure of the phase IIb study on danuglipron is a significant blow to Pfizer's (PFE) efforts to take a share of the growing market of GLP-1 drugs for treating obesity.",
            "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/82/41137.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.127847,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.114137",
                    "ticker_sentiment_score": "0.08737",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AMGN",
                    "relevance_score": "0.170475",
                    "ticker_sentiment_score": "0.109247",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.22595",
                    "ticker_sentiment_score": "0.229561",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "PFE",
                    "relevance_score": "0.333257",
                    "ticker_sentiment_score": "-0.002375",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Ozempic Lawsuit  ( December Update ) ",
            "url": "https://www.forbes.com/advisor/legal/product-liability/ozempic-lawsuit/",
            "time_published": "20231204T091641",
            "authors": [
                "Sarah Edwards"
            ],
            "summary": "Ozempic, a brand name for the drug semaglutide, is one of the newest weight management medications on the market. It has been in the news recently as an effective anti-obesity drugs. However, Ozempic is also much in the news for potentially dangerous side effects.",
            "banner_image": "https://www.forbes.com/advisor/wp-content/uploads/2023/11/Ozempic-Lawsuit-month-Update.png",
            "source": "Forbes",
            "category_within_source": "n/a",
            "source_domain": "www.forbes.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": -0.223677,
            "overall_sentiment_label": "Somewhat-Bearish",
            "ticker_sentiment": [
                {
                    "ticker": "NVO",
                    "relevance_score": "0.238718",
                    "ticker_sentiment_score": "-0.204378",
                    "ticker_sentiment_label": "Somewhat-Bearish"
                }
            ]
        },
        {
            "title": "The New Generation Of Weight-loss Drugs",
            "url": "https://www.barrons.com/news/the-new-generation-of-weight-loss-drugs-a6057612",
            "time_published": "20231204T032200",
            "authors": [
                "AFP - Agence France Presse"
            ],
            "summary": "Wegovy, Mounjaro, Ozempic... These new drugs drawing such intense attention have raised the hopes of millions around the world suffering from diabetes or obesity. But what are they, how are they used and who makes them?",
            "banner_image": "https://asset.barrons.com/barrons/images/afp-metadata-default.jpg",
            "source": "Barrons",
            "category_within_source": "n/a",
            "source_domain": "www.barrons.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.016982,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "GLDAF",
                    "relevance_score": "0.12165",
                    "ticker_sentiment_score": "-0.017836",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.353898",
                    "ticker_sentiment_score": "-0.038367",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "PFE",
                    "relevance_score": "0.12165",
                    "ticker_sentiment_score": "-0.017836",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Chasing Weight Loss Dream, Many In US Seek Ozempic Alternatives",
            "url": "https://www.barrons.com/news/chasing-weight-loss-dream-many-in-us-seek-ozempic-alternatives-5f06246b",
            "time_published": "20231204T024900",
            "authors": [
                "Daniel STUBLEN"
            ],
            "summary": "Like many Americans struggling to lose weight, Marissa Montanino felt compelled to try Ozempic or one of the other new so-called \"wonder drugs\" described as revolutionary in the fight against obesity. \"I would work out sometimes three times a day, I was doing hours worth of classes.",
            "banner_image": "https://www.barrons.com/asset/external-media/afp/AFP3028672167551846509121974704471751118582---2.jpg",
            "source": "Barrons",
            "category_within_source": "n/a",
            "source_domain": "www.barrons.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.5"
                }
            ],
            "overall_sentiment_score": -0.021913,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "META",
                    "relevance_score": "0.050148",
                    "ticker_sentiment_score": "-0.017107",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.100099",
                    "ticker_sentiment_score": "0.037495",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        }
    ]
}